<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Acta Neuropathol</journal-id><journal-id journal-id-type="iso-abbrev">Acta Neuropathol</journal-id><journal-title-group><journal-title>Acta Neuropathologica</journal-title></journal-title-group><issn pub-type="ppub">0001-6322</issn><issn pub-type="epub">1432-0533</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28401333</article-id><article-id pub-id-type="pmc">5508034</article-id><article-id pub-id-type="publisher-id">1709</article-id><article-id pub-id-type="doi">10.1007/s00401-017-1709-7</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Interactions of pathological proteins in neurodegenerative diseases</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2530-0598</contrib-id><name><surname>Spires-Jones</surname><given-names>Tara L.</given-names></name><address><email>tara.spires-jones@ed.ac.uk</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Attems</surname><given-names>Johannes</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Thal</surname><given-names>Dietmar Rudolf</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 7988</institution-id><institution-id institution-id-type="GRID">grid.4305.2</institution-id><institution>Centre for Dementia Prevention, and Euan MacDonald Centre for Motor Neurone Disease, </institution><institution>The University of Edinburgh Centre for Cognitive and Neural Systems, </institution></institution-wrap>1 George Square, Edinburgh, EH8 9JZ UK </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0462 7212</institution-id><institution-id institution-id-type="GRID">grid.1006.7</institution-id><institution>Institute of Neuroscience, </institution><institution>Newcastle University, </institution></institution-wrap>Campus for Ageing and Vitality, Newcastle upon Tyne, NE4 5PL UK </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0668 7884</institution-id><institution-id institution-id-type="GRID">grid.5596.f</institution-id><institution>Departement Neurowetenschappen, </institution><institution>Katholieke Universiteit Leuven, </institution></institution-wrap>Herestraat 49, 3000 Leuven, Belgium </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0626 3338</institution-id><institution-id institution-id-type="GRID">grid.410569.f</institution-id><institution>Departement Pathologische Ontleedkunde, </institution><institution>UZ Leuven, </institution></institution-wrap>Herestraat 49, 3000 Leuven, Belgium </aff></contrib-group><pub-date pub-type="epub"><day>11</day><month>4</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>11</day><month>4</month><year>2017</year></pub-date><pub-date pub-type="ppub"><year>2017</year></pub-date><volume>134</volume><issue>2</issue><fpage>187</fpage><lpage>205</lpage><history><date date-type="received"><day>9</day><month>1</month><year>2017</year></date><date date-type="rev-recd"><day>30</day><month>3</month><year>2017</year></date><date date-type="accepted"><day>1</day><month>4</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Neurodegenerative diseases such as Alzheimer&#x02019;s disease (AD), frontotemporal lobar degeneration (FTD), Lewy body disease (LBD), Parkinson&#x02019;s disease (PD), and amyotrophic lateral sclerosis (ALS) have in common that protein aggregates represent pathological hallmark lesions. Amyloid &#x003b2;-protein, &#x003c4;-protein, &#x003b1;-synuclein, and TDP-43 are the most frequently aggregated proteins in these disorders. Although they are assumed to form disease-characteristic aggregates, such as amyloid plaques and neurofibrillary tangles in AD or Lewy bodies in LBD/PD, they are not restricted to these clinical presentations. They also occur in non-diseased individuals and can co-exist in the same brain without or with a clinical picture of a distinct dementing or movement disorder. In this review, we discuss the co-existence of these pathologies and potential additive effects in the human brain as well as related functional findings on cross-seeding and molecular interactions between these aggregates/proteins. We conclude that there is evidence for interactions at the molecular level as well as for additive effects on brain damage by multiple pathologies occurring in different functionally important neurons. Based upon this information, we hypothesize a cascade of events that may explain general mechanisms in the development of neurodegenerative disorders: (1) distinct lesions are a prerequisite for the development of a distinct disease (e.g., primary age-related tauopathy for AD), (2) disease-specific pathogenic events further trigger the development of a specific disease (e.g., A&#x003b2; aggregation in AD that exaggerate further A&#x003b2; and AD-related &#x003c4; pathology), (3) the symptomatic disease manifests, and (4) neurodegenerative co-pathologies may be either purely coincidental or (more likely) have influence on the disease development and/or its clinical presentation.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Alzheimer&#x02019;s disease</kwd><kwd>Amyotrophic lateral sclerosis</kwd><kwd>Frontotemporal lobar degeneration</kwd><kwd>Lewy body</kwd><kwd>Amyloid beta</kwd><kwd>Tau</kwd><kwd>Synuclein</kwd><kwd>TDP-43</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002283</institution-id><institution>Alzheimer&#x02019;s Research UK</institution></institution-wrap></funding-source><award-id>ARUK-SPG2013-1</award-id><principal-award-recipient><name><surname>Spires-Jones</surname><given-names>Tara L.</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004440</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source><award-id>WT-ISSF</award-id><principal-award-recipient><name><surname>Spires-Jones</surname><given-names>Tara L.</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000781</institution-id><institution>European Research Council</institution></institution-wrap></funding-source><award-id>ALZSYN</award-id><principal-award-recipient><name><surname>Spires-Jones</surname><given-names>Tara L.</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010146</institution-id><institution>Alzheimer Forschung Initiative</institution></institution-wrap></funding-source><award-id>#13803</award-id><principal-award-recipient><name><surname>Thal</surname><given-names>Dietmar Rudolf</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution>FWO</institution></funding-source><award-id>Odysseus Funding</award-id><principal-award-recipient><name><surname>Thal</surname><given-names>Dietmar Rudolf</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution>Vlanderin Government</institution></funding-source><award-id>Vlaamse Impulsfinanciering voor Netwerken voor Dementieonderzoek</award-id><principal-award-recipient><name><surname>Thal</surname><given-names>Dietmar Rudolf</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000265</institution-id><institution>Medical Research Council</institution></institution-wrap></funding-source><award-id>G0400074</award-id><principal-award-recipient><name><surname>Attems</surname><given-names>Johannes</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag GmbH Germany 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">Neurodegenerative disorders are characterized by protein aggregates, the importance of which in inducing neuronal toxicity has been hotly debated. Pathological forms of proteins also appear to spread through the brain in characteristic patterns in most neurodegenerative diseases, with particularly robust evidence for the spread of amyloid beta (A&#x003b2;), tau (&#x003c4;), and &#x003b1;-synuclein (&#x003b1;-syn) [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR73">73</xref>]. Although each neurodegenerative disorder exhibits accumulation of specific characteristic protein aggregates, there are also many cases that exhibit aggregation of multiple pathological proteins. Studies in model systems including transgenic animals and cell culture support several potential types of interactions between different pathological proteins involved in neurodegeneration including cross-seeding of aggregates and pathological changes in one protein initiating mislocalization and post-translational modifications of another. Here, we will examine the neuropathological co-occurrence of pathologies in human autopsy cases and discuss potential mechanistic links between these diverse proteins in disease pathogenesis. We will focus on the pathological proteins for which there is the clearest evidence of both co-existence in human cases and biological evidence for potential mechanistic interactions. Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> summarizes the neurodegenerative diseases we will cover and the protein aggregates most commonly observed in the brains of people with those diagnoses. The co-occurrence of cerebrovascular pathology and protein aggregates is discussed in the other article of this cluster [<xref ref-type="bibr" rid="CR77">77</xref>]. Here, our aim is to provide an updated view about the co-occurrence of different protein aggregates in neurodegeneration and their possible mutual interactions which should further our understanding of the biology of neurodegenerative disorders.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Pathological aggregates in neurodegenerative diseases</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Disease</th><th align="left">Proteins that aggregate</th><th align="left">Location of aggregates</th><th align="left">Brain region(s) affected</th><th align="left">Common co-pathologies (% cases where observed)</th></tr></thead><tbody><tr><td align="left">AD</td><td align="left">Amyloid beta (A&#x003b2;)&#x02014;plaques and cerebral amyloid angiopathy (CAA)<break/>&#x003c4;-Protein&#x02014;neurofibrillary tangles (NFTs), neuropil threads (NTs)</td><td align="left">Extracellular with the neuropil (plaques), tunica media and at the basement membrane of cerebral and leptomeningeal blood vessels (CAA)<break/>Intracellular within the perikaryon and neuritic cytoplasm of neurons (NFTs, NTs)</td><td align="left">Plaques spread from neocortices to the allocortex and down through the basal ganglia, diencephalon, brain stem and cerebellum<break/>NFTs spread from transentorhinal cortex into hippocampus and the neocortex</td><td align="left">TDP-43 cytoplasmic inclusions (over 50% of cases) [<xref ref-type="bibr" rid="CR71">71</xref>]<break/>&#x003b1;-Syn Lewy neurites and LB (over 40% of cases) [<xref ref-type="bibr" rid="CR150">150</xref>]</td></tr><tr><td align="left">Tauopathies (FTLD-tau, Pick&#x02019;s disease, argyrophilic grain disease, frontotemporal dementia with chromosome 17 mutation, NFT-predominant dementia, PSP, CBD, PART)</td><td align="left">&#x003c4;-Protein&#x02014;NFTs, NTs, Pick bodies, coiled bodies, astrocytic plaques, tufted astrocytes, grains, ballooned neurons</td><td align="left">Cytoplasmic (neurons and glia)</td><td align="left">Frontal and temporal cortex, basal ganglia, and brain stem</td><td align="left">except for argyrophilic grain disease which frequently co-occurs with AD pathology, most cases do not have significant co-pathologies</td></tr><tr><td align="left">Synucleinopathies (Parkinson&#x02019;s/DLB/MSA)</td><td align="left">&#x003b1;-Syn&#x02014;LB, Lewy neurites (DLB/PD), glial cytoplasmic inclusions (Papp-Lantos bodies, MSA)</td><td align="left">Cytoplasmic [neurons&#x02014;PD, DLB; oligodendrocytes (Papp-Lantos bodies)&#x02014;MSA)]; nuclear (neurons&#x02014;MSA)</td><td align="left">Substantia nigra, cortex. In PD, pathology begins in brainstem and spreads up through midbrain to cortex. In DLB, pathology begins in cortex and spreads &#x0201c;down&#x0201d;<break/>MSA-P (striato-nigral degeneration with parkinsonism (SDN)): lesions mainly in the striatum and the substantia nigra; gray and white matter pathology<break/>MSA-C (olivo-ponto-cerebellar atrophy, OPCA): lesions mainly in the pons, medulla oblongata, and the cerebellum; gray and white matter pathology</td><td align="left">A&#x003b2; pathology (over 80% of cases) [<xref ref-type="bibr" rid="CR61">61</xref>]<break/>NFT and NT at Braak stage &#x0003e;II (over 50% of cases) [<xref ref-type="bibr" rid="CR61">61</xref>]<break/>TDP-43 pathology (over 30%) [<xref ref-type="bibr" rid="CR95">95</xref>]</td></tr><tr><td align="left">Amyotrophic lateral sclerosis (ALS)</td><td align="left">TDP-43, FUS, ubiquilin, C9orf72 translated intronic repeat, SOD1</td><td align="left">Cytoplasmic, nuclear (neurons and oligodendrocytes)</td><td align="left">Motor cortex, spinal cord, other cortical regions</td><td align="left">Neurofibrillary tangles (78%), atherosclerosis (35%); &#x003b2;-amyloid (35%); tauopathy/tau inclusions (17%), Lewy body formation (11%), microinfarcts (7%), and &#x003b1;-syn (4%) [<xref ref-type="bibr" rid="CR24">24</xref>]<break/>&#x003c4;- and &#x003b1;-syn pathology in cases of the Kii-Peninsula variant in the temporal lobe, striatum brain stem, cerebellum [<xref ref-type="bibr" rid="CR82">82</xref>, <xref ref-type="bibr" rid="CR102">102</xref>]</td></tr><tr><td align="left">FTLD-TDP, FTLD-FUS</td><td align="left">TDP-43, FUS, ubiquilin, C9orf72 translated intronic repeat</td><td align="left">Cytoplasmic, nuclear inclusions in neurons and glial cells</td><td align="left">Frontotemporal neocortex and medial temporal lobe</td><td align="left"/></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec2"><title>A&#x003b2; and &#x003c4;&#x02014;interactions of the classic hallmarks of Alzheimer&#x02019;s disease (AD)</title><p id="Par3">AD is the most common dementing disorder seen in 50&#x02013;60% of dementia cases. Neuropathologically, AD is characterized by dramatic atrophy of the gray matter and accumulation of amyloid plaques and neurofibrillary tangles (NFTs) [<xref ref-type="bibr" rid="CR60">60</xref>]. Amyloid plaques consist of extracellular aggregates of A&#x003b2; [<xref ref-type="bibr" rid="CR93">93</xref>], which is a cleavage product derived from the amyloid precursor protein (APP) by &#x003b2;- and &#x003b3;-secretase cleavage [<xref ref-type="bibr" rid="CR53">53</xref>]. The same A&#x003b2; peptide also occurs in AD-related vascular deposits known as cerebral amyloid angiopathy (CAA) [<xref ref-type="bibr" rid="CR7">7</xref>]. A&#x003b2;-plaques as well as vascular A&#x003b2; deposits first occur in neocortical areas and then expand into further brain regions in a distinct hierarchical sequence [<xref ref-type="bibr" rid="CR141">141</xref>, <xref ref-type="bibr" rid="CR143">143</xref>].</p><sec id="Sec3"><title>Age-related accumulation of A&#x003b2; and &#x003c4;</title><p id="Par4">Age is the most important risk factor for Alzheimer&#x02019;s disease, and for most sporadic, non-inherited neurodegenerative disorders. However, the question of why age is associated with increased risk for neurodegeneration remains unclear. We have examined pathological cohorts at different ages to characterize pathological accumulations. A&#x003b2; deposits are observed as early as 11&#x02013;20&#x000a0;years of age, and their frequency and phase of distribution increases with increasing age. At 80&#x000a0;years of age, approx. 80% of all autopsy cases show A&#x003b2; plaques (see also Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>b), whereas approx. 20% do not develop any amyloid plaques up to the age of 100&#x000a0;years [<xref ref-type="bibr" rid="CR15">15</xref>]. Symptomatic AD seen in the old age groups exhibits a prevalence ranging from 11% in the age group over 64&#x000a0;years to 32% in the age group over 84&#x000a0;years [<xref ref-type="bibr" rid="CR3">3</xref>]. In parallel with the &#x003c4; and A&#x003b2; pathology, neuritic plaques also become more prevalent with aging. In the cohort of cases covered in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>c, they were first seen between 41&#x02013;60&#x000a0;years of age and reached approximately 55% prevalence in the age group of 81&#x02013;100&#x000a0;years. Amyloid pathology alone is not sufficient to cause symptomatic Alzheimer&#x02019;s disease, and many non-demented people show early phases of plaque pathology with aging.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Pathological proteins accumulate with increasing age as measured in large post-mortem studies. Age-related prevalence of NFTs (<bold>a</bold>, <italic>n</italic>&#x000a0;=&#x000a0;1310), A&#x003b2; plaques (<bold>b</bold>, <italic>n</italic>&#x000a0;=&#x000a0;849), neuritic plaques (<bold>c</bold>, <italic>n</italic>&#x000a0;=&#x000a0;662), AD pathology as defined by NIA-AA (<bold>d</bold>, <italic>n</italic>&#x000a0;=&#x000a0;662), TDP-43 pathology (<bold>e</bold>, <italic>n</italic>&#x000a0;=&#x000a0;147), and Lewy body pathology (<bold>f</bold>, <italic>n</italic>&#x000a0;=&#x000a0;582) (reevaluation of previously published cases by the authors (JA, DRT) [<xref ref-type="bibr" rid="CR95">95</xref>, <xref ref-type="bibr" rid="CR139">139</xref>, <xref ref-type="bibr" rid="CR146">146</xref>, <xref ref-type="bibr" rid="CR147">147</xref>]). The prevalence for NFTs is provided separately for each Braak-NFT stage (I&#x02013;VI) [<xref ref-type="bibr" rid="CR12">12</xref>] (<bold>a</bold>) and that for A&#x003b2; plaques separately for each phase of A&#x003b2;-plaque deposition as determined in medial temporal lobe sections (<italic>1</italic>&#x02013;<italic>4</italic>) [<xref ref-type="bibr" rid="CR144">144</xref>] corresponding with the plaques extension all over the entire brain [<xref ref-type="bibr" rid="CR143">143</xref>]. The frequency of neuritic plaques (<bold>c</bold>) is shown separately for each CERAD score (<italic>1</italic>&#x02013;<italic>3</italic>) [<xref ref-type="bibr" rid="CR98">98</xref>]. The neuritic plaques were detected in these cases by Gallyas silver staining or immunohistochemistry against abnormal phosphorylated &#x003c4;-protein (AT-8) [<xref ref-type="bibr" rid="CR142">142</xref>, <xref ref-type="bibr" rid="CR146">146</xref>]. The degree of AD pathology has been assessed in accordance with the current neuropathological criteria for the description of AD pathology as published by the National Institute of Aging and the Alzheimer Association [low (1)&#x02014;high (3)] [<xref ref-type="bibr" rid="CR60">60</xref>] (<bold>d</bold>). The prevalence of TDP-43 aggregates was assessed dichotomously on the basis of an immunostaining with an antibody against phosphorylated TDP-43 (presence&#x000a0;=&#x000a0;1) (<bold>e</bold>). The prevalence of LB pathology was assessed by classifying the LB pathology according to Braak et al. (<italic>1</italic>&#x02013;<italic>6</italic>) [<xref ref-type="bibr" rid="CR14">14</xref>]. Prevalences were provided separately for each stage (<bold>f</bold>). In contrast, to &#x003c4;, A&#x003b2;, and TDP-43 pathology, the prevalence of LB pathology decreases after a peek in the age group 61&#x02013;80&#x000a0;years probably indicating a life expectancy limiting effect of LB pathology</p></caption><graphic xlink:href="401_2017_1709_Fig1_HTML" id="MO1"/></fig>
</p><p id="Par5">NFTs represent neuronal cytoplasmic aggregates of abnormal &#x003c4;-protein that form paired helical filaments [<xref ref-type="bibr" rid="CR48">48</xref>]. The first step in the formation of these aggregates is the abnormal phosphorylation of the &#x003c4;-protein, the dissociation of &#x003c4; from axonal microtubules, and its aberrant accumulation in the somatic cytoplasm and dendrites. Somatodendritic accumulations of phosphorylated &#x003c4; before fibrils are formed and are called &#x0201c;pretangles&#x0201d; [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. NFTs consisting of paired helical filaments of &#x003c4; develop after (and presumably directly from) pretangles and correlate with neuronal degeneration. NFTs remain as ghost tangles even after the death of neurons, but the amount of neuronal death in AD exceeds the amount of NFT formation, indicating that NFTs are not necessary for cell death [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. In the human brain, silver-stainable NFTs start to develop in the transentorhinal cortex and in a few subcortical brain stem nuclei (locus coeruleus, raphe nuclei, basal nucleus of Meynert) [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. From the transentorhinal cortex, NFT pathology spreads into the entorhinal region and then further into other brain regions in a distinct hierarchical sequence that is different from that for A&#x003b2;-plaques [<xref ref-type="bibr" rid="CR12">12</xref>]. The &#x003c4;-protein occurs in the human brain in six isoforms, which have a characteristic microtubule-binding repeat region [<xref ref-type="bibr" rid="CR44">44</xref>]. Three &#x003c4; isoforms have 3 repeats in the repeat region, whereas the other three isoforms have 4 repeats. In AD, both 3- and 4-repeat isoforms are detected in the &#x003c4;-aggregates [<xref ref-type="bibr" rid="CR44">44</xref>].</p><p id="Par6">As with A&#x003b2;, the prevalence of &#x003c4; pathology increases with age but can be detected in surprisingly young people. The earliest signs of an abnormal accumulation/aggregation have been found in a 6-year-old boy [<xref ref-type="bibr" rid="CR13">13</xref>] in the locus coeruleus (the brainstem nucleus that represents the noradrenergic center of the brain) exhibiting non-fibrillar abnormal phosphorylated &#x003c4;-protein. These first &#x003c4;-accumulations were pretangles. Pretangles were seen in other brainstem and subcortical nuclei, namely the raphe nuclei (serotonergic brain stem nuclei), and the basal nucleus of Meynert (cholinergic nuclei of the brain) at later ages. At 40&#x000a0;years of age, most human individuals showed brainstem &#x003c4; pathology [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. The first NFTs consisting of paired helical filaments were seen in individuals between 10 and 20&#x000a0;years of age, but the question of whether these NFTs are already associated with AD or if they are unrelated to AD remains controversial [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. However, with advancing age, NFT-&#x003c4; pathology becomes more prevalent and higher Braak-NFT stages also become more prevalent. In people over 91&#x000a0;years of age, nearly every individual shows at least Braak-NFT stage 1 [<xref ref-type="bibr" rid="CR15">15</xref>] (see also Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>a).</p><p id="Par7">Neurofibrillary tangle pathology is not exclusively found in association with A&#x003b2; deposition as evidenced by the disease primary age-related tauopathy (PART). PART is characterized by the presence of neuronal &#x003c4;-protein pathology in the form of neurofibrillary tangles (NFT) and neuropil threads (NT) without (definite PART) or with only limited (possible PART) parenchymal amyloid-&#x003b2; (A&#x003b2;) depositions (up to phase 2 according to Thal et al. [<xref ref-type="bibr" rid="CR143">143</xref>]) [<xref ref-type="bibr" rid="CR28">28</xref>]. In addition, any other primary tauopathy (such as PSP, CBD, and AGD, etc.) has to be excluded. PART is frequent in old age (up to 40%) and is likely to represent the neuropathological correlate of a condition termed &#x0201c;suspected non-AD pathophysiology&#x0201d; (SNAP), which refers to individuals with temporal lobe atrophy on MRI and high CSF &#x003c4; but no evidence for cerebral A&#x003b2; depositions [<xref ref-type="bibr" rid="CR64">64</xref>]. SNAP is usually seen in cognitively normal elderly but may also be present in mildly impaired individuals. While the neuroanatomical progression of NFT/NT in PART follows AD-associated NFT-Braak stages [<xref ref-type="bibr" rid="CR28">28</xref>], the latter do not exceed stage IV in PART and NFT-Braak stages V/VI are indeed only seen in the presence of A&#x003b2; pathology.</p><p id="Par8">As PART is a rather novel entity, little is known about the co-occurrence of PART and other neurodegenerative diseases. However, in the Newcastle Brain Tissue Resource (NBTR), 12% of LBD cases show additional PART and in 45% of PART cases, pathological lesions typically associated with other diseases were present (e.g., ALS, stroke, multiple system atrophy), while 55% of all PART cases showed no signs of neurological disease during life and no or only very mild age-associated pathologies at post-mortem examination in addition to PART.</p></sec><sec id="Sec4"><title>Mechanistic links between A&#x003b2; and &#x003c4;</title><p id="Par9">Despite the existence of &#x0201c;pure&#x0201d; or &#x0201c;primary&#x0201d; tauopathies, it is clear that A&#x003b2; and &#x003c4; pathologies are related, at least in AD. The link between A&#x003b2; and &#x003c4; pathologies is clearly evidenced in their convergence in the AD brain as neuritic plaques, in which A&#x003b2; aggregates are associated with dystrophic neurites, which most frequently exhibit neurofibrillary lesions consisting of aggregates of abnormal phosphorylated &#x003c4;-protein [<xref ref-type="bibr" rid="CR32">32</xref>]. Here, intracellular &#x003c4; in dystrophic neurites together with extracellular A&#x003b2; constitute one single pathological lesion, i.e., the neuritic plaque, which is a conditio sine qua non for the neuropathological diagnosis of symptomatic AD. Although plaque and tangle pathologies begin in different brain regions and show different progression pattern (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>; Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>), a recent PET imaging study found some convergence zones of A&#x003b2; and &#x003c4; pathologies, particularly in the inferior-lateral temporal lobe, which hints at physical, perhaps network-distributed interactions of these pathologies in disease progression [<xref ref-type="bibr" rid="CR123">123</xref>].</p><p id="Par10">Further evidence strongly implicating a mechanistic link between A&#x003b2; and &#x003c4; is the genetics of familial AD (fAD), which clearly implicates changes in A&#x003b2; processing not only in plaque formation but also in causing &#x003c4; pathology. fAD mutations have been found in the APP gene, which codes for the amyloid precursor protein (APP) that is cleaved to form A&#x003b2;, and also in the presenilin 1 and 2 genes (PSEN1, PSEN2) [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR120">120</xref>, <xref ref-type="bibr" rid="CR130">130</xref>, <xref ref-type="bibr" rid="CR131">131</xref>], which form parts of the &#x003b3;-secretase enzyme responsible for one of the essential proteolytic cleavages of APP to form A&#x003b2; [<xref ref-type="bibr" rid="CR161">161</xref>]. Pathogenic mutations in these genes lead to an increased production of A&#x003b2; and to the development of AD. Neuropathologically, these cases show A&#x003b2; and &#x003c4; aggregates similar to those observed in sporadic AD cases. In further support of A&#x003b2; generation being key to initiating AD, other mutations in the APP gene that preclude A&#x003b2; production have been shown to be protective [<xref ref-type="bibr" rid="CR69">69</xref>]. Conversely, mutations in the <italic>MAPT</italic> gene encoding &#x003c4; do not cause fAD, but can lead to neurodegenerative tauopathies which often include Parkinsonian symptoms [<xref ref-type="bibr" rid="CR59">59</xref>]. Here, &#x003c4; pathology occurs in neurons, astrocytes, and oligodendrocytes in a FTLD-tau-like pattern, sometimes producing Pick bodies. Co-occurrence of other neurodegenerative features except for age-related amounts are uncommon. The pattern in FTLD-tau cases with &#x003c4;-mutations is very variable [<xref ref-type="bibr" rid="CR40">40</xref>]. The <italic>MAPT</italic> gene occurs on a part of chromosome 17 that has two major haplotypes called H1 and H2 due to an ancient inversion of a 900&#x000a0;kb region [<xref ref-type="bibr" rid="CR132">132</xref>], and these haplotypes have been linked to the risk of several diseases. H1 haplotype is associated with increased risk of the tauopathies progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) and more recently to the risk of developing late-onset AD (LOAD) in people who do not carry the well-established LOAD risk gene APOE4 [<xref ref-type="bibr" rid="CR110">110</xref>]. A relatively recently discovered mutation in <italic>MAPT</italic>, A152T, was discovered in a PSP patient and was subsequently found to be associated with increased risk of FTD, PSP, CBD, and AD [<xref ref-type="bibr" rid="CR27">27</xref>].</p><p id="Par11">Along with the co-occurrence of A&#x003b2; and &#x003c4; pathologies in AD brain, and the human genetic data strongly suggesting that increased production of A&#x003b2; may trigger &#x003c4; pathology, data in model systems also support a series of complex interactions between A&#x003b2; and &#x003c4;. Mouse models have been developed, which exhibit plaques due to overexpression of fAD-associated mutant proteins and &#x003c4; pathology due to overexpression of FTD-associated mutant &#x003c4;. Generally, the results of these studies support the role of A&#x003b2; in exacerbating &#x003c4; pathology. For example, crossing Tg2576 mice which develop A&#x003b2; pathology and JNPL3 tauopathy mice exacerbated the &#x003c4; pathology [<xref ref-type="bibr" rid="CR87">87</xref>]. In the 3xTg mice, which similarly have both A&#x003b2; and &#x003c4; pathology, lowering A&#x003b2; levels causes a reduction in &#x003c4; pathology, but conversely lowering &#x003c4; levels does not reduce A&#x003b2; pathology [<xref ref-type="bibr" rid="CR108">108</xref>, <xref ref-type="bibr" rid="CR157">157</xref>], again arguing that A&#x003b2; is upstream of &#x003c4; pathology. In further support of this idea, mice that expresses human oligomeric A&#x003b2; and human &#x003c4; eventually develop NFT pathology even in the absence of tauopathy-associated mutations in the MAPT gene [<xref ref-type="bibr" rid="CR152">152</xref>]. Moreover, in cell culture experiments, applying exogenous A&#x003b2; to mouse primary neurons instigates &#x003c4; phosphorylation and mislocalization to dendrites [<xref ref-type="bibr" rid="CR163">163</xref>], and in human stem cell-derived neuronal cultures, overexpressing fAD mutations in APP and PS1 causes both plaque and tangle pathology [<xref ref-type="bibr" rid="CR21">21</xref>]. Most of the evidence from genetics, mouse models, and cells indicates that A&#x003b2; drives &#x003c4; pathology, but there are examples of surprising reciprocal interactions. For example, in the APP/PS1 mouse model, plaques are significantly larger in mice expressing either human P301L mutant [<xref ref-type="bibr" rid="CR114">114</xref>] or wild-type human &#x003c4; [<xref ref-type="bibr" rid="CR65">65</xref>]. Not only does A&#x003b2; appear to somehow instigate &#x003c4; pathology, it may also gate the spread of &#x003c4; pathology through the brain. A recent cross-sectional PET study examining both A&#x003b2; and &#x003c4; indicates this potential effect with hints that A&#x003b2; pathology is necessary to start the spread of &#x003c4; pathology out of the medial temporal lobe [<xref ref-type="bibr" rid="CR123">123</xref>]. These imaging data accurately reflect neuropathological findings as &#x003c4; pathology in the absences of A&#x003b2; (i.e., PART) does not exceed NFT-Braak stage IV, while NFT-Braak stages V/VI are only seen in the presence of A&#x003b2; further indicating an aggravating effect of A&#x003b2; on &#x003c4; pathology. Similar to findings in the human brain, in rTgTauEC mice expressing FTD mutant &#x003c4; restricted to the entorhinal cortex, the presence of plaques (generated by crossing the rTgTauEC line with APP/PS1 mice) accelerates the spread of &#x003c4; through neural circuits [<xref ref-type="bibr" rid="CR114">114</xref>]. However, while A&#x003b2; may aggravate &#x003c4; pathology, it is not a prerequisite for the mere development of &#x003c4; pathology and hence A&#x003b2; must not be regarded as a mandatory upstream event in the development of &#x003c4; pathology. The existence of non-AD tauopathies such as PSP, Pick&#x02019;s disease, and CBD strongly support the point of view that A&#x003b2; is not required to develop a tauopathy that cases neurological/psychiatric symptoms.</p><p id="Par12">While pathological lesions of A&#x003b2; are mainly extracellular and &#x003c4; lesions are intracellular, there are places in the brain where the soluble forms of these proteins, which are now thought to be the more toxic, bioactive species, may interact. One such important point of convergence is the synapse. Several factors indicate that synapses are key players in AD pathogenesis: (1) synapse dysfunction and loss occur early in the disease process (2) synapse loss is the strongest pathological correlate of cognitive decline, and (3) synaptic connections appear to be the point of spread of pathological proteins through neural circuits. A large body of literature shows that pathological soluble forms of A&#x003b2; and &#x003c4; can separately induce synaptic dysfunction and synapse loss, and more recently, evidence has begun to accumulate linking A&#x003b2; and &#x003c4; in synapse degeneration [<xref ref-type="bibr" rid="CR128">128</xref>]. Removing endogenous mouse &#x003c4; protects mice against some A&#x003b2;-mediated synaptic phenotypes such as seizure activity, synaptotoxicity, and long-term potentiation deficits [<xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR119">119</xref>, <xref ref-type="bibr" rid="CR124">124</xref>], and the synapse loss observed with exogenous A&#x003b2; application to cultured neurons is associated with local accumulations of phosphorylated &#x003c4; in dendrites [<xref ref-type="bibr" rid="CR163">163</xref>]. A&#x003b2; and &#x003c4; were also shown with immuno-electron microscopy to co-accumulate in postsynaptic terminals in 3xTg AD mice [<xref ref-type="bibr" rid="CR136">136</xref>], although due to the limitations of electron microscopy, this was in a limited number of animals and was not quantified. We are using the array tomography technique to allow higher throughput quantitative imaging of synapses than EM and to overcome the <italic>z</italic>-resolution limit of light microscopy and accurately study the colocalization of pathological proteins of synapses in mouse and human brain with immunofluorescence [<xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR97">97</xref>]. These studies indicate that these proteins do co-occur in a subset of synapses in both mouse and human brain (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). Our recent work in a novel mouse model indicates that there is not a strict dose&#x02013;response relationship in the interactions of A&#x003b2; and &#x003c4; in synapse loss as addition of wild-type human &#x003c4; in APP/PS1 mice with plaque-associated synapse loss does not exacerbate synapse loss [<xref ref-type="bibr" rid="CR65">65</xref>]. Future work with temporal control over &#x003c4; reduction in these plaque-bearing mice will determine whether &#x003c4; is necessary for A&#x003b2;-mediated synaptic phenotypes. Another potential mechanistic interaction at the synapse between proteins involved in different diseases is the role of cellular prion protein (PrPc) in A&#x003b2;-mediated synapse degeneration. PrPc becomes misfolded, aggregated, and toxic in Prion diseases such as variant Creutzfeldt&#x02013;Jakob disease. In addition, PrPc has been proposed as a co-receptor with mGluR5 for oligomeric A&#x003b2; at synapses where it activates Fyn kinase and causes impaired synaptic plasticity [<xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR85">85</xref>, <xref ref-type="bibr" rid="CR151">151</xref>]. This is a potentially very interesting cascade in light of the role of Fyn kinase in mediating &#x003c4; toxicity at synapses, thus linking three pathological proteins in the same synaptotoxic cascade, at least in mouse models.<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Co-aggregation of pathological proteins in synapses may contribute to neurodegeneration. Synaptic toxicity of pathological proteins is thought to be one of the driving forces in several neurodegenerative diseases. In both a mouse model expressing fAD mutations in APP and PS1 and human wild-type &#x003c4; ([<xref ref-type="bibr" rid="CR65">65</xref>], <italic>top</italic>) and human AD brain (<italic>bottom</italic>), we observe colocalization of A&#x003b2; and &#x003c4; at some synapses using the array tomography technique (<italic>arrows</italic>). <italic>Scale bars</italic> represent 5&#x000a0;&#x000b5;m in large panel and 2&#x000a0;&#x000b5;m in <italic>inset</italic>
</p></caption><graphic xlink:href="401_2017_1709_Fig2_HTML" id="MO2"/></fig>
</p></sec></sec><sec id="Sec5"><title>Overlap of &#x003b1;-syn with other pathologies</title><p id="Par13">Synucleinopathies encompass Lewy body diseases (LBD) and multiple system atrophy (MSA). The latter are characterized by glial &#x003b1;-syn aggregations in the form of glial cytoplasmic inclusions (Papp-Lantos bodies) while the neuropathological hallmark lesions of LBD are &#x003b1;-syn aggregates in neuronal cell somata and neuronal cell processes termed Lewy bodies (LB) and Lewy neurites (LN), respectively. LBD encompass Parkinson&#x02019;s disease (PD), Parkinson&#x02019;s disease dementia (PDD), and dementia with LB (DLB). While PD is primarily a movement disorder clinically characterized by the presence of extrapyramidal symptoms (EPS), clinical core features of PDD and DLB include fluctuating cognition and visual hallucinations [<xref ref-type="bibr" rid="CR96">96</xref>]. There are no neuropathological criteria that allow to distinguish between PDD and DLB as this distinction can only be made based on clinical grounds; in PDD, EPS precede the onset of dementia by at least 12&#x000a0;months, whereas in DLB dementia is concomitant with or precedes EPS [<xref ref-type="bibr" rid="CR96">96</xref>].</p><p id="Par14">There are several neuropathological staging systems for LBD, the most frequently used are the Braak LBD stages and the Newcastle/McKeith criteria for LBD. Briefly, Braak LBD stages [<xref ref-type="bibr" rid="CR14">14</xref>] postulate that nuclei in the medulla oblongata become initially affected (stage 1) and pathology spreads gradually to pons (stage 2), midbrain (stage 3), entorhinal cortex, and hippocampus (stage 4) and finally reaches the neocortex (stages 5 and 6). This topographical progression is not proposed in the Newcastle/McKeith criteria [<xref ref-type="bibr" rid="CR96">96</xref>], which distinguish between brainstem predominant (PD), limbic (transitional; DLB), and diffuse neocortical (DLB) types of LBD. &#x003b1;-Syn aggregates in the form of LB do not show a continuous increase with increasing age. Instead, the degree and prevalence of Lewy body pathology started in the 41- to 60-year-old age group and then increased up 61&#x02013;80&#x000a0;years of age. In older individuals, the prevalence of the lesions at the different stages decreased (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>f). This decrease of Lewy body pathology is unexpected and could be explained by a reduced life expectancy of Lewy body pathology patients compared with that of AD patients. However, confirmation in independent samples and further, more detailed studies are required to clarify these findings.</p><p id="Par15">While the neuropathological hallmark lesions of LBDs are LB/LN other pathologies are highly prevalent in LBDs; A&#x003b2; depositions are present in up to 85% of LBD cases with dementia [<xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR76">76</xref>] and it has been suggested that striatal A&#x003b2; pathology is less frequent in PDD as compared to DLB (e.g., 18 vs. 100% in [<xref ref-type="bibr" rid="CR76">76</xref>]), while in PD, A&#x003b2; pathology is in general less frequent (e.g., 55% in [<xref ref-type="bibr" rid="CR66">66</xref>]) than in LBD with dementia. Similarly, &#x003c4; pathology is frequently present in LBD [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR76">76</xref>] and a recently published study on 213 LBD cases with dementia found that 30% showed high Braak NFT stages V/VI [<xref ref-type="bibr" rid="CR61">61</xref>]. Such cases which show neocortical LBD (i.e., DLB) and full-blown AD (i.e., Braak NFT stages V/VI) can be neuropathologically diagnosed as having mixed dementia (mixed AD/DLB), since the severity of either AD or LB pathology alone would be sufficient to represent a robust neuropathological correlate for clinical dementia. This raises the question as to why those cases clinically either present as DLB or AD. Using quantitative assessment of A&#x003b2;, &#x003c4;-protein, and &#x003b1;-syn in such mixed AD/DLB we found that those who clinically presented with AD had higher &#x003c4; loads than those with clinical LBD [<xref ref-type="bibr" rid="CR156">156</xref>]. Moreover, the hierarchical distribution of &#x003c4;-protein loads in clinical AD cases was similar to neuropathologically pure AD cases, while clinical DLB cases showed comparatively less hippocampal and temporal &#x003c4; loads. These findings suggest that in clinical AD cases neuropathologically diagnosed as mixed AD/DLB neurodegeneration may be primarily driven by AD while LB pathology occurs later in the disease, possibly aggravated or even triggered by AD pathology. Conversely, in clinically diagnosed DLB cases, which show mixed AD/DLB at post-mortem examination, classical LB pathology (i.e., &#x003b1;-syn) may be the primary driver of the neurodegenerative process. While these data somehow suggest that in mixed cases the quantitatively predominant pathology determines the characteristic clinical pictures, a large clinico-pathological correlative study using conventional semi-quantitative methodology found in a subset of clinically diagnosed DLB cases only severe neocortical &#x003c4; pathology and a complete lack of LB pathology [<xref ref-type="bibr" rid="CR105">105</xref>]. Recently, Irwin and colleagues demonstrated that &#x003c4; pathology in LBD with dementia independently predicted a shorter time interval between motor symptom and dementia onset as well as shorter overall survival [<xref ref-type="bibr" rid="CR61">61</xref>], clearly indicating that&#x02014;if present&#x02014;&#x003c4; plays a central role in the disease process of LBD and that the co-occurrence of both AD and DLB pathology is likely to have an aggravating effect on disease progression. Respective data from neuropathological post-mortem studies are corroborated by in vivo imaging studies showing higher amyloid and &#x003c4; levels in LBD compared to controls [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>]. While AD pathology is the most important co-morbidity in LBD cases, they may also show other pathologies such as cerebrovascular disease to varying degrees of severity in up to 75% [<xref ref-type="bibr" rid="CR67">67</xref>] and TDP-43 pathology in over 30% of cases [<xref ref-type="bibr" rid="CR95">95</xref>]. More quantitative data on the amount of pathological burden in large clinico-pathological cohorts are needed to clarify the relative influence of A&#x003b2;, &#x003c4;, &#x003b1;-syn, and TDP-43 on the clinical picture. This would pave the way for novel and more subtle clinico-pathological phenotypes, which, together with biomarkers, would allow to diagnose patients based on the actual underlying pathology.</p><p id="Par16">Genetic data provide a tenuous link between synucleinopathies and tauopathies. H1 &#x003c4; haplotype is associated with increased risk of PD [<xref ref-type="bibr" rid="CR155">155</xref>], and has recently been associated with increased &#x003b1;-syn aggregation in DLB in a small post-mortem study [<xref ref-type="bibr" rid="CR25">25</xref>]. There is also cross-talk between &#x003b1;-syn and &#x003c4; in terms of disease-associated mutations. Mutations in or replications of the <italic>SCNA</italic> gene encoding &#x003b1;-syn that cause familial PD can also cause cognitive symptoms including dementia [<xref ref-type="bibr" rid="CR104">104</xref>, <xref ref-type="bibr" rid="CR113">113</xref>, <xref ref-type="bibr" rid="CR126">126</xref>]. A recent genetic study indicates that the p.A152T variant of <italic>MAPT</italic> is likely associated with a higher risk of DLB [<xref ref-type="bibr" rid="CR84">84</xref>]. Another potential genetic link between &#x003c4; and &#x003b1;-syn is LRRK2. LRRK2 mutations usually give rise to &#x003b1;-syn pathology [<xref ref-type="bibr" rid="CR52">52</xref>], but sometimes, they also cause tangle pathology. &#x003c4; and &#x003b1;-syn pathology can also occur hand in hand without amyloid plaque pathology in rare cases, e.g., with hereditary spastic paraplegia due to SPG 7 mutations [<xref ref-type="bibr" rid="CR148">148</xref>].</p><p id="Par17">In addition to genetic data implying causative links between tauopathies and synucleinopathies, there are also multiple indications that pathological forms of &#x003c4; and &#x003b1;-syn physically co-aggregate within neuronal cytoplasm [<xref ref-type="bibr" rid="CR104">104</xref>]. Using double immunofluorescence labeling and mass-spectrometry, &#x003c4; and &#x003b1;-syn have been observed in several studies to aggregate together in the same tangles, LB, and Lewy Neurites in PD and DLB brain [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR62">62</xref>]. Importantly, one recent study using novel conformation-specific antibodies demonstrated that toxic oligomeric forms of &#x003c4; and &#x003b1;-syn accumulate together in PD and DLB [<xref ref-type="bibr" rid="CR122">122</xref>]. In vitro, &#x003b1;-syn binds directly to &#x003c4; via the microtubule-binding region of the &#x003c4; protein and the C-terminus of &#x003b1;-syn [<xref ref-type="bibr" rid="CR68">68</xref>]. This interaction is affected in a complex and as yet not completely understood manner by both phosphorylation and disease-associated mutations in the proteins [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR104">104</xref>]. It is possible that &#x003c4; and &#x003b1;-syn through their binding can cross-seed aggregation. Amyloidogenic proteins share some common characteristics in terms of their aggregation with a typically slow initial aggregation that becomes much faster after the process begins due to the new aggregates templating or seeding further aggregation [<xref ref-type="bibr" rid="CR81">81</xref>]. This seeding process is not only relevant to the formation of large fibrils but also to the formation of oligomeric forms of proteins, which are likely the toxic species in the brain [<xref ref-type="bibr" rid="CR81">81</xref>]. The seeding process is not necessarily limited to seeds made from the aggregating protein. Indeed, cross-seeding, in which &#x0201c;seeds&#x0201d;&#x02014;some type of small aggregate&#x02014;from one protein can induce aggregation of another protein&#x02014;has been demonstrated across many different proteins. There is a small amount of evidence suggesting that &#x003c4; and A&#x003b2; may cross-seed the formation of toxic aggregates in vitro [<xref ref-type="bibr" rid="CR49">49</xref>]. Much more evidence implicates cross-seeding between &#x003b1;-syn and &#x003c4;. In vitro, co-incubation of &#x003b1;-syn and &#x003c4; synergistically promotes aggregation of both proteins [<xref ref-type="bibr" rid="CR41">41</xref>], and in cultured neurons expressing FTDP-17 mutant &#x003c4;, synthetic aggregates of &#x003b1;-syn seeded &#x003c4; [<xref ref-type="bibr" rid="CR50">50</xref>]. However, the cross-seeding of these proteins is not always reproduced, for example, using a sensitive FRET-based detection method, &#x003c4; and &#x003b1;-syn did not cross-seed [<xref ref-type="bibr" rid="CR55">55</xref>]. These conflicting results may be due to the ability of specific &#x0201c;strains&#x0201d; or confirmations of aggregates of the proteins, which induce the seeding, which has been observed for &#x003c4; [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR37">37</xref>], &#x003b1;-syn [<xref ref-type="bibr" rid="CR111">111</xref>], and cross-seeding between them [<xref ref-type="bibr" rid="CR50">50</xref>]. Similarly, distinct strains of A&#x003b2; have been observed, which induce different types of aggregates in vivo [<xref ref-type="bibr" rid="CR133">133</xref>, <xref ref-type="bibr" rid="CR159">159</xref>]. Cross-seeding between A&#x003b2; and &#x003b1;-syn has been observed in vitro [<xref ref-type="bibr" rid="CR109">109</xref>], along with hybrid oligomer formation [<xref ref-type="bibr" rid="CR149">149</xref>]. Further work is warranted on understanding the cross-seeding process, and particularly on whether this causes the formation of toxic oligomeric species of the proteins.</p><p id="Par18">Transgenic mouse models of tauopathies and synucleinopathies also support the idea of synergistic interactions of &#x003c4; and &#x003b1;-syn in exacerbating neurodegenerative phenotypes. Overexpressing &#x003b1;-syn in transgenic mice causes &#x003c4; phosphorylation [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR160">160</xref>]. Combining pathologies in mice overexpressing fAD mutations in <italic>APP</italic> and <italic>PSEN1</italic>, FTDP-17 mutant <italic>MAPT</italic>, and PD associated <italic>SCNA</italic>, there is a synergistic effect of the pathological proteins resulting in exacerbated pathological and behavioral phenotypes [<xref ref-type="bibr" rid="CR23">23</xref>]. Knocking out &#x003c4;, however, does not prevent &#x003b1;-syn-related motor deficits in two models of PD, indicating that these proteins in addition to having synergistic effects can act independently to confer toxicity [<xref ref-type="bibr" rid="CR103">103</xref>]. In wild-type mice injected with &#x003b1;-syn fibrils, both &#x003c4; and TDP-43 aggregate in addition to &#x003b1;-syn [<xref ref-type="bibr" rid="CR94">94</xref>]. There is also a substantial amount of evidence for cross-talk between A&#x003b2; and &#x003b1;-syn pathologies. NMR evidence shows molecular interactions between these proteins [<xref ref-type="bibr" rid="CR91">91</xref>], and in a double transgenic mouse model, A&#x003b2; exacerbates &#x003b1;-syn accumulation and neuronal deficits [<xref ref-type="bibr" rid="CR92">92</xref>]. A&#x003b2; induces phosphorylation of &#x003b1;-syn at Ser129 in vitro and pSer129 &#x003b1;-syn in brain tissue homogenates is related to the level of A&#x003b2; and Braak NFT stage [<xref ref-type="bibr" rid="CR135">135</xref>]. Similar to Alzheimer&#x02019;s disease, there is also evidence that synaptic degeneration is important in synucleinopathies with pathology associated with synaptic toxicity in vitro and in vivo [<xref ref-type="bibr" rid="CR127">127</xref>, <xref ref-type="bibr" rid="CR154">154</xref>]. Less is known about molecular interactions of pathological proteins in synapse degeneration in synucleinopathies. &#x003c4; reduction did not prevent motor deficits in &#x003b1;-syn overexpressing mice, indicating that &#x003c4; is not necessary for synaptic deficits in this line [<xref ref-type="bibr" rid="CR103">103</xref>].</p></sec><sec id="Sec6"><title>The frontotemporal lobar degeneration: amyotrophic lateral sclerosis (FTLD-ALS) spectrum and beyond</title><p id="Par19">Both FTLD and ALS are heterogeneous diseases that can be sub-divided by their pathological lesions. Over the past few years, a substantial overlap has been observed in the pathologies, genetics, and clinical phenotypes of these complex diseases. FTLD can be subclassified in disorders that accumulate (1) &#x003c4;, i.e., FTLD-tau, (2) TDP-43, i.e., FTLD-TDP, and (3) other FTLD-forms that accumulate other proteins (e.g., fused in sarcoma (FUS) etc.) [<xref ref-type="bibr" rid="CR90">90</xref>]. FTLD-TDP and ALS share neuronal TDP-43 aggregates and a certain number of ALS cases also develop FTLD-TDP and vice versa [<xref ref-type="bibr" rid="CR107">107</xref>].</p><p id="Par20">FTLD-tau comprises several morphologically different tauopathies: Pick&#x02019;s disease (PiD), corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), argyrophilic grain disease (AGD), and neurofibrillary tangle-predominant dementia (NFTD) [<xref ref-type="bibr" rid="CR90">90</xref>]. All these diseases have in common that &#x003c4; is the sole protein that aggregates in these disorders. These diseases usually affect individuals below 70&#x000a0;years of age and concomitant AD-associated A&#x003b2; and &#x003c4; as well as TDP-43 and LBD-associated &#x003b1;-syn may potentially be present but are only rarely seen [<xref ref-type="bibr" rid="CR147">147</xref>] and hence not assumed to influence the disease process. Moreover, &#x003c4; pathology in FTLD-tau is, except for NFTD, not restricted to neurons and neuronal processes. It also develops in astrocytes (astrocytic plaques in CBD, tufted astrocytes in PSP, &#x003c4;-positive astrocytes in AGD) and oligodendrocytes (coiled bodies in AGD, CBD, PSP, PiD) [<xref ref-type="bibr" rid="CR33">33</xref>]. Except for AGD, FTLD-tau disorders cause dementia and in most cases do not show co-pathologies [<xref ref-type="bibr" rid="CR147">147</xref>]. AGD is usually present with low-level AD-related pathology and such cases do not show clinical dementia [<xref ref-type="bibr" rid="CR72">72</xref>, <xref ref-type="bibr" rid="CR145">145</xref>]. Demented AGD cases, however, showed significantly more severe AD-related pathology (A&#x003b2;-plaques and NFTs) than non-demented AGD cases but less than in demented cases that had pure AD pathology, suggesting additive effects of AGD and AD pathology [<xref ref-type="bibr" rid="CR72">72</xref>, <xref ref-type="bibr" rid="CR145">145</xref>]. &#x003c4; pathology is also observed in some ALS cases, where it has been reported to correlate with cognitive decline [<xref ref-type="bibr" rid="CR162">162</xref>].</p><p id="Par21">FTLD-TDP is characterized by intracellular aggregates of phosphorylated TDP-43 in the neuronal cytoplasm, dendrites [<xref ref-type="bibr" rid="CR107">107</xref>] as well as in oligodendroglial cells [<xref ref-type="bibr" rid="CR106">106</xref>]. In FTLD-TDP and ALS cases, not only full length TDP-43 aggregates are found, but also truncated fragments, mainly C-terminal fragments of TDP-43, are also found [<xref ref-type="bibr" rid="CR107">107</xref>]. In a subset of FTLD-TDP and ALS cases, hexanucleotide repeat expansions in the chromosome 9 open reading frame 72 (<italic>C9ORF72</italic>) have been seen. In these mutation carriers, dipeptide aggregates corresponding to abnormal translation of the pathological hexanucleotide repeats can be seen in the cytoplasm of neurons [<xref ref-type="bibr" rid="CR101">101</xref>]. However, these aggregates do not correlate with disease severity or the coexisting TDP-43 pathology in the studies reported so far. The amount of TDP-43 pathology correlates more closely with the clinical severity of the disease in the studies conducted to date [<xref ref-type="bibr" rid="CR89">89</xref>]. TDP-43 pathology in patients with the behavioral variant of FTLD-TDP (FTLD-TDP cases that show characteristic behavioral changes as key feature of the disease&#x000a0;=&#x000a0;bvFTLD-TDP) and with sporadic ALS show a characteristic pattern that suggests anatomical stages of TDP-43 pathology spreading that differed among bvFTLD-TDP and ALS [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR18">18</xref>].</p><p id="Par22">TDP-43 pathology is also found in AD cases [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR153">153</xref>]. Recently, Josephs and colleagues reported that TDP-43 pathology in AD is seen in over 50% of cases where it spreads in a distinct pattern [<xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR71">71</xref>], which was also observed in LBD and aged controls by others [<xref ref-type="bibr" rid="CR95">95</xref>]. Moreover, colocalization of phosphorylated TDP-43 and &#x003c4;-containing NFTs has been reported but it is not yet clear whether this finding is due to unspecific co-staining of NFTs with the pTDP-43 antibody or whether indeed phosphorylated TDP-43 accumulates in NFTs. A similar questionable colocalization of &#x003c4; and TDP-43 is speculated in granulovacuolar degeneration (GVD) [<xref ref-type="bibr" rid="CR75">75</xref>]. GVD has been shown to represent an AD-related lesion [<xref ref-type="bibr" rid="CR139">139</xref>] exhibiting phosphorylated TDP-43 as well as numerous other proteins in neuronal cytoplasmic vacuoles including &#x003c4; [<xref ref-type="bibr" rid="CR34">34</xref>] and phosphorylated A&#x003b2; [<xref ref-type="bibr" rid="CR83">83</xref>].</p><p id="Par23">There is substantial overlap in the genetics of FTD and ALS [<xref ref-type="bibr" rid="CR115">115</xref>]. Mutations in <italic>C9ORF72</italic>, <italic>TARDBP, FUS, VCP, UBQLN2</italic>, <italic>SQSTM1</italic>, and <italic>CHMP2B</italic> have all been associated with both ALS and FTD [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR84">84</xref>], and mutations in <italic>hgRNPA2B1</italic> and can cause multisystem proteinopathy and ALS [<xref ref-type="bibr" rid="CR80">80</xref>]. <italic>TARDBP</italic> mutations (TDP-43 gene) can lead to FTLD-TDP and/or rare ALS cases. Usually, no other proteins are aggregated in non-age-related amounts in these cases [<xref ref-type="bibr" rid="CR74">74</xref>]. However, a case report shows a <italic>TARDBP</italic> mutation in a fAD case indicating a potential link from TDP-43 directly to AD [<xref ref-type="bibr" rid="CR100">100</xref>]. <italic>C9ORF72</italic> mutations go in most instances along with TDP-43 pathology either with a FTLD-TDP or an ALS-related pattern [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR116">116</xref>]. In single cases, AD-related pathology also occurred as relevant pathological lesion in <italic>C9ORF72</italic> mutation carriers, but the interpretation of this finding is controversial [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR54">54</xref>]. One of the most interesting aspects of <italic>C9ORF72</italic> mutations is that in families with a distinct <italic>C9ORF72</italic> mutation, the same mutation in some family members causes FTLD, whereas other family members with the same mutation developed ALS [<xref ref-type="bibr" rid="CR20">20</xref>]. As such, other factors than the mutations appear to act as disease modifiers with impact on the primary vulnerability of distinct neurons. Since the C9orf72-related dipeptide aggregates do not correlate with the clinical symptomatology but with the TDP-43 pathology [<xref ref-type="bibr" rid="CR107">107</xref>, <xref ref-type="bibr" rid="CR121">121</xref>], it is tempting to speculate that TDP-43-specific properties play a role in the primary targeting of the disease. In rare cases, mutations in the valosin-containing protein lead to FTLD-TDP or ALS [<xref ref-type="bibr" rid="CR158">158</xref>]. Here, nuclear TDP-43-valosin-containing protein aggregates are the predominant lesion although cytoplasmic TDP-43 aggregates can also in different amounts [<xref ref-type="bibr" rid="CR107">107</xref>, <xref ref-type="bibr" rid="CR121">121</xref>]. In this disorder, similar aggregates were found in skeletal muscle and in the myocardium [<xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR158">158</xref>].</p><p id="Par24">Pathological proteins typically associated with ALS and FTLD also show multiple mutual interactions including co-aggregation [<xref ref-type="bibr" rid="CR10">10</xref>]. An interesting phenomenon emerging in the ALS protein aggregation literature is the role of low complexity domains in the RNA-binding proteins implicated in disease pathogenesis contributing to pathological protein aggregation. Low complexity domains mediate liquid&#x02013;liquid phase separation which in healthy cells contributes to the assembly of membrane-less organelles such as RNA transport granules and stress granules; but in disease, the liquid phase transition initiates fibrillization of aggregates [<xref ref-type="bibr" rid="CR99">99</xref>]. This may explain the co-aggregation of different low complexity domain-containing proteins such as TDP-43 and FUS [<xref ref-type="bibr" rid="CR79">79</xref>]. Interestingly, dipeptide repeat proteins produced from unconventional non-ATG dependent translation of <italic>C9ORF72</italic> expansions, the most common cause of ALS and FTLD, have recently been found to interact with RNA-binding proteins with low complexity sequence domains in Drosophila [<xref ref-type="bibr" rid="CR86">86</xref>]. This finding provides a potentially unifying mechanism for the disparate causes of ALS/FTLD converging on disrupted phase transitions that impair the assembly, dynamics, and function of membrane-less organelles that cause widespread cellular abnormalities including impairments in nucleolar function, nucleocytoplasmic transport, RNA splicing, translation, and abnormal protein aggregation.</p></sec><sec id="Sec7"><title>Discussion</title><p id="Par25">Here, we have reviewed neuropathological and experimental findings, which together point to pathogenic links between the aggregation of A&#x003b2;, &#x003c4;, TDP-43, and &#x003b1;-syn. These links are most evident in fAD cases with mutations in the <italic>APP</italic>, <italic>PSEN1</italic>, or <italic>PSEN2</italic> genes because these cases often show aggregates of all four proteins in the brain due to mutation-driven production of high amounts of A&#x003b2;. Even a larger number of sporadic AD cases exhibit A&#x003b2;, &#x003c4;, and TDP-43 aggregates [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR153">153</xref>]. Given the fact that &#x003c4;-aggregates develop in restricted areas of the brain before A&#x003b2;, TDP-43, and &#x003b1;-syn lesions occur, one could speculate that &#x003c4; pathology initiates AD and the aggregation of other proteins is just a secondary phenomenon. However, most people will accumulate brainstem &#x003c4; pathology (usually between 40 and 50&#x000a0;years of age) [<xref ref-type="bibr" rid="CR15">15</xref>] but only 32% will develop symptomatic AD in their lifetimes [<xref ref-type="bibr" rid="CR3">3</xref>], and genetic evidence strongly implicates changes in A&#x003b2; as crucial for initiating the disease process. Thus, &#x003c4; pathology alone appears not to be sufficient to develop AD as defined according to the recommended criteria [<xref ref-type="bibr" rid="CR60">60</xref>], A&#x003b2; pathology must also be involved. In other words, one can hypothesize that accumulation and aggregation of abnormal &#x003c4;-protein aggregates is an age-related phenomenon, which becomes overtly pathogenic and allowed to spread throughout the brain in the presence of A&#x003b2; aggregates. Post-translationally modified forms of A&#x003b2;, such as A&#x003b2;<sub>N3pE</sub> and <sub>pSer8</sub>A&#x003b2;, may play an important role in the maturation of these aggregates [<xref ref-type="bibr" rid="CR117">117</xref>]. Thus, maturation of protein aggregates, especially A&#x003b2; aggregates, appears to play a major role in the development of the disease [<xref ref-type="bibr" rid="CR117">117</xref>]. In animal models for A&#x003b2; pathology, A&#x003b2; pathology alone is not sufficient to develop the full spectrum of AD pathology [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR134">134</xref>], although it is possible that this is in part due to the lifespan of rodents and in part due to differences in rodent and human &#x003c4;. Notwithstanding these caveats, the A&#x003b2;-expressing animal model findings do support our hypothesis that &#x003c4; pathology is an essential prerequisite for the development of AD but only in combination with A&#x003b2;. &#x003c4;-mutations in the absence of A&#x003b2; (in man and in transgenic mice) lead mainly to a non-AD tauopathy and only very rarely are associated with AD [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR59">59</xref>]. Moreover, the AD pathology in APP mutation carriers develops in adulthood after a normal childhood, i.e., when &#x003c4; pathology becomes more and more prevalent in the published autopsy cohorts meaning that once abnormal &#x003c4; occurs, the disease starts to develop, implying that &#x003c4; is a prerequisite for disease.</p><p id="Par26">Interactions between A&#x003b2; and TDP-43 or &#x003b1;-syn may follow similar principles as that with &#x003c4;. The AD-specific progression pattern of AD-related TDP-43 aggregates [<xref ref-type="bibr" rid="CR70">70</xref>] is different from that in FTLD-TDP and ALS cases [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR18">18</xref>], which argues in favor of the idea that A&#x003b2; also exaggerates AD-related TDP-43 pathology. An argument for the interaction between A&#x003b2; and &#x003b1;-syn aggregates may be the frequent coincidence of full-blown AD and LBD pathology in demented patients that were clinically diagnosed as LBD patients (PDD and/or DLB), as well as the detection of LBDs in fAD cases [<xref ref-type="bibr" rid="CR88">88</xref>, <xref ref-type="bibr" rid="CR125">125</xref>]. Moreover, in the absence of A&#x003b2;, TARDBP and <italic>SCNA</italic> mutations do not cause AD but ALS or PD [<xref ref-type="bibr" rid="CR74">74</xref>, <xref ref-type="bibr" rid="CR100">100</xref>, <xref ref-type="bibr" rid="CR113">113</xref>].</p><p id="Par27">Other proteins (in addition to A&#x003b2;) may also have triggering effects for neurodegeneration. The most attractive candidates are dipeptide aggregates in C9ORF72 hexanucleotide repeat mutation carriers developing ALS or FTLD-TDP with TDP-43 aggregates [<xref ref-type="bibr" rid="CR101">101</xref>]. Moreover, a case report also suggests that mutant paraplegin (<italic>SPG7</italic> mutation) triggers both brainstem &#x003c4; and &#x003b1;-syn pathology in the absence of A&#x003b2; [<xref ref-type="bibr" rid="CR148">148</xref>]. That one MAPT mutation causes &#x003b1;-syn changes in addition to &#x003c4; pathology and that a mutation in LRRK2 can induce both, &#x003b1;-syn&#x02014;and in a few cases &#x003c4;&#x02014;pathology [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR84">84</xref>] further argues for a link between &#x003b1;-syn and &#x003c4;.</p><p id="Par28">Thus, several proteins can lead to neurodegeneration alone or in concert with one another. Intraneuronal and intracellular protein aggregates appear to be most relevant for the neurodegenerative process because they occur in all of the discussed neurodegenerative disorders and correlate well with cognitive decline and neuron loss [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR138">138</xref>]. It appears that the neuropathological type of neurodegenerative disorder simply reflects the circumstances of protein aggregation and that the pathogenic process of protein aggregation behind the phenotype has common principles in several neurodegenerative disorders, such as spreading of disease-related pathology [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR143">143</xref>] and the involvement of post-translationally modified proteins in the disease-specific aggregates [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR107">107</xref>, <xref ref-type="bibr" rid="CR140">140</xref>].</p><p id="Par29">An argument for the hypothesis that the &#x0201c;phenotype of neurodegeneration&#x0201d; is the result of a critical accumulation of soluble and/or insoluble protein aggregates in neurons&#x02014;regardless of the protein that aggregates&#x02014;is provided by an artificial mouse model that produces intraneuronal A&#x003b2; aggregates after cleavage from an enkephalin-signal-peptide A&#x003b2;<sub>42</sub> construct, which shows significant neuron loss and an ALS-like phenotype with serious motor dysfunction (APP48 mice) [<xref ref-type="bibr" rid="CR1">1</xref>]. Under this artificial paradigm, A&#x003b2; and/or its soluble and/or insoluble aggregates show different neurodegenerative effects than under the more AD-related paradigm of APP overexpression [<xref ref-type="bibr" rid="CR118">118</xref>]. However, post-translational modification of A&#x003b2; similar to that seen in AD cases also occurred in the intracellular A&#x003b2;<sub>42</sub> aggregates in this artificial mouse model [<xref ref-type="bibr" rid="CR118">118</xref>] indicating that post-translational modifications may play an important role for the neurodegeneration process in general. Thus, artificial expression of an aggregation-prone protein in neurons causes neurodegeneration similar to other intraneuronal proteins that develop aggregates such as &#x003c4; or TDP-43, whereas mainly extracellular deposition of the same protein had only limited effects supporting the idea that the intracellular protein accumulation may be a prerequisite for neurodegeneration, whereas extracellular A&#x003b2; aggregates may catalyze spreading of intracellular aggregates while interacting and aggregating with the respective proteins.</p><p id="Par30">The above-mentioned considerations argue against the classical view of the amyloid cascade hypothesis insofar as A&#x003b2; does not seem to the one and only player that causes all the rest of AD pathology. Amyloid as a key factor in AD pathogenesis is strongly supported, particularly by genetics of fAD, but it is also clear that alone, amyloid pathology is insufficient to drive neurodegeneration. The weight of the evidence on mechanisms of neuron loss in AD sides with &#x003c4; being the driving toxic force. The data we have summarized here on co-occurrence of amyloid and &#x003c4;-pathologies in human brain and their mechanistic interactions in model systems support the intriguing possibility that in sporadic AD, age-related &#x003c4;-accumulation as observed in PART occurs earlier and independently from A&#x003b2;, thus representing a prerequisite for A&#x003b2; to kick off the pathogenesis of AD. In the event that both proteins in an aggregated form co-occur in the brain, they appear to become particularly toxic and presumably interact to lead to the devastating neurodegeneration in AD. Lesions typical for other neurodegenerative disorders or vascular lesions may co-exist and either interact with the AD-related protein aggregates or producing brain lesions that are added to the AD-related neurodegeneration. Other tauopathies, TDP-43 proteinopathies, and synucleinopathies may follow a similar cascade of prerequisite lesion plus secondary disease-specific pathogenic event as depicted in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>.<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Cascade hypothesis for neurodegenerative disorders: Pathological protein interactions contribute to neurodegeneration. Schematic representation of the interplay between the different neurodegenerative protein aggregates and their related diseases. As a result of the current knowledge about disease progression and experimental evidence about protein-aggregate interactions in vivo an in vitro, we hypothesize that abnormal &#x003c4;-protein accumulation is an event that happens during aging in the brain stem of nearly everyone above 40&#x000a0;years of age [<xref ref-type="bibr" rid="CR15">15</xref>] (<italic>1</italic> prerequisite for disease). AD appears to develop when A&#x003b2; aggregates occur and initiate more pathological accumulation of &#x003c4; and its spread through the brain (<italic>2</italic> disease-specific pathogenic event and <italic>3</italic> disease). Maturation of plaque-associated and soluble/dispersible A&#x003b2;-aggregates thereby appear to be a critical event in the progression of the disease. Abnormal &#x003c4;-protein aggregates, TDP-43 aggregates, and &#x003b1;-syn aggregates occur in smaller subset of individuals during age as shown in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> (it is not clear whether it is a result of aging or the early stages of neurodegeneration). Once A&#x003b2; aggregates prevail in a certain amount or biochemical maturation stage, it is tempting to speculate that these A&#x003b2; aggregates may also exaggerate/catalyze TDP-43 or possibly also &#x003b1;-syn pathology in pattern similar to that seen in AD or AD-LBD (<italic>4</italic> &#x003b1;-syn pathology is typical for PD/DLB and can be interpreted as pure coincidence or as influenced by/influencing AD pathology or its clinical picture). In the absence of A&#x003b2; and/or after exposure to other triggers (e.g., disease-specific mutations, excitotoxicity in Guam disease [<xref ref-type="bibr" rid="CR35">35</xref>]) &#x003c4;, &#x003b1;-syn, and TDP-43 aggregates develop other neurodegenerative disorders such as FTLD-tau, FTLD-TDP, ALS, or PD/DLB. <italic>AD</italic> Alzheimer&#x02019;s disease, <italic>FTLD</italic> frontotemporal lobar degeneration, <italic>ALS</italic> amyotrophic lateral sclerosis (synonymous with MND&#x02014;motor neuron disease), <italic>LBD</italic> Lewy body disease [including Parkinson&#x02019;s disease (PD) and DLB]</p></caption><graphic xlink:href="401_2017_1709_Fig3_HTML" id="MO3"/></fig>
</p><p id="Par31">One critical point in this cascade hypothesis is the point that mutation-driven disease might need a prerequisite lesion. One can argue that the mutations will drive even the initial lesions. However, if this would be the case, mutation-driven neurodegenerative disorders should manifest earlier in life during childhood because the mutant genes are expressed even at that age. However, most frequently, these disorders manifest usually in the 4th&#x02013;6th decade of life or later [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR129">129</xref>, <xref ref-type="bibr" rid="CR130">130</xref>, <xref ref-type="bibr" rid="CR137">137</xref>]. Accordingly, an age-related event seems to be required before the mutant protein can set a disease-specific pathogenic event. This concept is to some degree in line with the two-hit concept for TDP-43-proteinopathies [<xref ref-type="bibr" rid="CR112">112</xref>].</p><p id="Par32">The accumulation of misfolded proteins in the human brain is clearly associated with advanced age. However, the underlying mechanisms of this age-associated phenomenon are still unclear and the respective role of, e.g., DNA damage, autophagy impairment, cellular senescence, oxidative stress, and mitochondrial dysfunction are yet to be elucidated. Such elucidation may also provide further insights into cerebral multimorbidity as the age-associated impairment of underlying mechanisms to maintain cellular homeostasis may vary between individuals, possibly based on their respective genetic background. For example, GWAS studies point toward a role of disturbed autophagic/lysosomal function in DLB but not in PDD, while the opposite was suggested for mitochondrial dysfunction. Therefore, the pathomechanisms of cerebral multimorbidity may not only be explained by protein&#x02013;protein interactions but also by age-associated failure of basic cellular mechanisms, which may show individual variations.</p><p id="Par33">The presence of multiple protein aggregates in patients with neurodegenerative symptoms indicates that in many cases not only one disease, such as AD is responsible for the clinical symptoms but that secondary components such as TDP-43 inclusions or even vascular lesions contribute to the development of the symptoms of a given patient as well. Thus, diagnostic and therapeutic regimes must not only focus on the most evident pathology such as AD but also need to take into account other neurodegenerative and vascular lesions. Thus, for the clinical diagnostic procedure, it appears to be essential to screen not only for AD lesions, but also for &#x003b1;-syn, TDP-43, and for vascular lesions.</p></sec><sec id="Sec8"><title>Conclusion</title><p id="Par34">&#x003c4;, TDP-43, and &#x003b1;-syn alone lead to specific neurodegenerative disorders that do not necessarily show multiple proteins aggregating in the respective disorders such as in FTLD-tau, FTLD-TDP, ALS, and PD, whereas AD appears to have at least a two-step pathogenesis with alterations in A&#x003b2; likely initiating the actual disease process, but with &#x003c4; accumulation and spread through the brain being the essential step to cause disease symptoms. It is possible that pathological accumulations of &#x003c4; independent of A&#x003b2; are a prerequisite for AD with extracellular A&#x003b2; being the second step that exaggerates or catalyzes the pathological process leading to clinical dementia. Similarly, TDP-43 and &#x003b1;-syn pathologies probably develop independently (and can cause clinical disease) but extracellular A&#x003b2; may aggravate or catalyze the spread of these pathologies throughout the brain. Accumulating evidence suggests that the fibrillar aggregates of all of these proteins are not likely directly toxic to neurons but reflect&#x02014;and in some cases exacerbate&#x02014;the accumulation of toxic soluble forms of the proteins.</p><p id="Par35">Data from human autopsy material and experimental model systems indicate multiple interactions of pathological proteins both directly in terms of co-aggregation and indirectly, for example, involvement in the same molecular pathways to neurodegeneration. Recent data also make it tempting to speculate that pathological proteins interact in the process of spread of the disease through the brain. However, our knowledge on cerebral multimorbidity is still limited as this multimorbidity shows considerable qualitative and quantitative heterogeneity between cases, and hence large-scale studies on human post-mortem brains, which combine both detailed clinical data and quantitative data on the amount of protein-aggregate burden, are needed to further our understanding of protein&#x02013;protein interactions in the multimorbid old brain. Understanding these interactions will be important to develop effective therapeutic targets to reduce toxicity and possibly to stop these diseases in their tracks (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>).</p></sec></body><back><fn-group><fn><p>Tara L. Spires-Jones, Johannes Attems and Dietmar Rudolf Thal contributed equally to this manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>TS-J is funded by Alzheimer&#x02019;s Research UK and the Scottish Chief Scientist&#x02019;s Office, Alzheimer&#x02019;s Society, a Wellcome Trust ISSF grant, and the European Research Council (ALZSYN). DRT received research grants from Alzheimer Forschung Initiative, Germany #13803, from FWO&#x02014;Odysseus funding, and from the government of Vlanderen VIND (Vlaamse Impulsfinanciering voor Netwerken voor Dementieonderzoek). JA used tissue for this study which was provided by the Newcastle Brain Tissue Resource, which is funded in part by a grant from the UK Medical Research Council (Grant Number G0400074) and by Brains for Dementia research, a joint venture between Alzheimer&#x02019;s Society and Alzheimer&#x02019;s Research UK. We gratefully acknowledge Dominic Walsh and Virginia Lee for providing antibodies used in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>.</p></ack><notes notes-type="COI-statement"><title>Compliance with ethical standards</title><sec id="FPar1"><title>Conflict of interest</title><p id="Par36">DRT received consultancies from Covance Laboratories (UK) and GE-Healthcare (UK), received a speaker honorarium from GE-Healthcare (UK), and collaborated with Novartis Pharma Basel (Switzerland). TS-J collaborates with Cognition Therapeutics (USA).</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abramowski</surname><given-names>D</given-names></name><name><surname>Rabe</surname><given-names>S</given-names></name><name><surname>Rijal Upadhaya</surname><given-names>A</given-names></name><name><surname>Reichwald</surname><given-names>J</given-names></name><name><surname>Danner</surname><given-names>S</given-names></name><name><surname>Staab</surname><given-names>D</given-names></name><name><surname>Capetillo-Zarate</surname><given-names>E</given-names></name><name><surname>Yamaguchi</surname><given-names>H</given-names></name><name><surname>Saido</surname><given-names>TC</given-names></name><name><surname>Wiederhold</surname><given-names>KH</given-names></name><etal/></person-group><article-title>Transgenic expression of intraneuronal Abeta42 but not Abeta40 leads to cellular Abeta lesions, degeneration and functional impairment without typical Alzheimer&#x02019;s disease pathology</article-title><source>J Neurosci</source><year>2012</year><volume>32</volume><fpage>1273</fpage><lpage>1283</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4586-11.2012</pub-id><pub-id pub-id-type="pmid">22279212</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alafuzoff</surname><given-names>I</given-names></name><name><surname>Arzberger</surname><given-names>T</given-names></name><name><surname>Al-Sarraj</surname><given-names>S</given-names></name><name><surname>Bodi</surname><given-names>I</given-names></name><name><surname>Bogdanovic</surname><given-names>N</given-names></name><name><surname>Braak</surname><given-names>H</given-names></name><name><surname>Bugiani</surname><given-names>O</given-names></name><name><surname>Del Tredici</surname><given-names>K</given-names></name><name><surname>Ferrer</surname><given-names>I</given-names></name><name><surname>Gelpi</surname><given-names>E</given-names></name><etal/></person-group><article-title>Staging of neurofibrillary pathology in Alzheimer&#x02019;s disease. A study of the BrainNet Europe Consortium</article-title><source>Brain Pathol</source><year>2008</year><volume>18</volume><fpage>484</fpage><lpage>496</lpage><pub-id pub-id-type="pmid">18371174</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Alzheimer&#x02019;s Association</collab></person-group><article-title>2016 Alzheimer&#x02019;s disease facts and figures</article-title><source>Alzheimers Dement</source><year>2016</year><volume>12</volume><fpage>459</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2016.03.001</pub-id><pub-id pub-id-type="pmid">27570871</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amador-Ortiz</surname><given-names>C</given-names></name><name><surname>Lin</surname><given-names>WL</given-names></name><name><surname>Ahmed</surname><given-names>Z</given-names></name><name><surname>Personett</surname><given-names>D</given-names></name><name><surname>Davies</surname><given-names>P</given-names></name><name><surname>Duara</surname><given-names>R</given-names></name><name><surname>Graff-Radford</surname><given-names>NR</given-names></name><name><surname>Hutton</surname><given-names>ML</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name></person-group><article-title>TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer&#x02019;s disease</article-title><source>Ann Neurol</source><year>2007</year><volume>61</volume><fpage>435</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1002/ana.21154</pub-id><pub-id pub-id-type="pmid">17469117</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arima</surname><given-names>K</given-names></name><name><surname>Mizutani</surname><given-names>T</given-names></name><name><surname>Alim</surname><given-names>MA</given-names></name><name><surname>Tonozuka-Uehara</surname><given-names>H</given-names></name><name><surname>Izumiyama</surname><given-names>Y</given-names></name><name><surname>Hirai</surname><given-names>S</given-names></name><name><surname>Ueda</surname><given-names>K</given-names></name></person-group><article-title>NACP/alpha-synuclein and tau constitute two distinctive subsets of filaments in the same neuronal inclusions in brains from a family of parkinsonism and dementia with Lewy bodies: double-immunolabeling fluorescence and electron microscopic studies</article-title><source>Acta Neuropathol</source><year>2000</year><volume>100</volume><fpage>115</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1007/s004010050002</pub-id><pub-id pub-id-type="pmid">10963357</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arriagada</surname><given-names>PV</given-names></name><name><surname>Growdon</surname><given-names>JH</given-names></name><name><surname>Hedley-Whyte</surname><given-names>ET</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name></person-group><article-title>Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer&#x02019;s disease</article-title><source>Neurology</source><year>1992</year><volume>42</volume><fpage>631</fpage><lpage>639</lpage><pub-id pub-id-type="doi">10.1212/WNL.42.3.631</pub-id><pub-id pub-id-type="pmid">1549228</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Attems</surname><given-names>J</given-names></name><name><surname>Jellinger</surname><given-names>K</given-names></name><name><surname>Thal</surname><given-names>DR</given-names></name><name><surname>Van Nostrand</surname><given-names>W</given-names></name></person-group><article-title>Review: sporadic cerebral amyloid angiopathy</article-title><source>Neuropathol Appl Neurobiol</source><year>2011</year><volume>37</volume><fpage>75</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2990.2010.01137.x</pub-id><pub-id pub-id-type="pmid">20946241</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Attems</surname><given-names>J</given-names></name><name><surname>Thomas</surname><given-names>A</given-names></name><name><surname>Jellinger</surname><given-names>K</given-names></name></person-group><article-title>Correlations between cortical and subcortical tau pathology</article-title><source>Neuropathol Appl Neurobiol</source><year>2012</year><volume>38</volume><fpage>582</fpage><lpage>590</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2990.2011.01244.x</pub-id><pub-id pub-id-type="pmid">22115520</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bancher</surname><given-names>C</given-names></name><name><surname>Brunner</surname><given-names>C</given-names></name><name><surname>Lassmann</surname><given-names>H</given-names></name><name><surname>Budka</surname><given-names>H</given-names></name><name><surname>Jellinger</surname><given-names>K</given-names></name><name><surname>Wiche</surname><given-names>G</given-names></name><name><surname>Seitelberger</surname><given-names>F</given-names></name><name><surname>Grundke-Iqbal</surname><given-names>I</given-names></name><name><surname>Iqbal</surname><given-names>K</given-names></name><name><surname>Wisniewski</surname><given-names>HM</given-names></name></person-group><article-title>Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer&#x02019;s disease</article-title><source>Brain Res</source><year>1989</year><volume>477</volume><fpage>90</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1016/0006-8993(89)91396-6</pub-id><pub-id pub-id-type="pmid">2495152</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blokhuis</surname><given-names>AM</given-names></name><name><surname>Groen</surname><given-names>EJN</given-names></name><name><surname>Koppers</surname><given-names>M</given-names></name></person-group><article-title>Protein aggregation in amyotrophic lateral sclerosis</article-title><source>Acta Neuropathol</source><year>2013</year><volume>125</volume><fpage>777</fpage><lpage>794</lpage><pub-id pub-id-type="doi">10.1007/s00401-013-1125-6</pub-id><pub-id pub-id-type="pmid">23673820</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braak</surname><given-names>E</given-names></name><name><surname>Braak</surname><given-names>H</given-names></name><name><surname>Mandelkow</surname><given-names>EM</given-names></name></person-group><article-title>A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads</article-title><source>Acta Neuropathol</source><year>1994</year><volume>87</volume><fpage>554</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1007/BF00293315</pub-id><pub-id pub-id-type="pmid">7522386</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braak</surname><given-names>H</given-names></name><name><surname>Braak</surname><given-names>E</given-names></name></person-group><article-title>Neuropathological stageing of Alzheimer-related changes</article-title><source>Acta Neuropathol</source><year>1991</year><volume>82</volume><fpage>239</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1007/BF00308809</pub-id><pub-id pub-id-type="pmid">1759558</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braak</surname><given-names>H</given-names></name><name><surname>Del Tredici</surname><given-names>K</given-names></name></person-group><article-title>The pathological process underlying Alzheimer&#x02019;s disease in individuals under thirty</article-title><source>Acta Neuropathol</source><year>2011</year><volume>121</volume><fpage>171</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1007/s00401-010-0789-4</pub-id><pub-id pub-id-type="pmid">21170538</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braak</surname><given-names>H</given-names></name><name><surname>Del Tredici</surname><given-names>K</given-names></name><name><surname>Rub</surname><given-names>U</given-names></name><name><surname>de Vos</surname><given-names>RA</given-names></name><name><surname>Jansen Steur</surname><given-names>EN</given-names></name><name><surname>Braak</surname><given-names>E</given-names></name></person-group><article-title>Staging of brain pathology related to sporadic Parkinson&#x02019;s disease</article-title><source>Neurobiol Aging</source><year>2003</year><volume>24</volume><fpage>197</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1016/S0197-4580(02)00065-9</pub-id><pub-id pub-id-type="pmid">12498954</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braak</surname><given-names>H</given-names></name><name><surname>Thal</surname><given-names>DR</given-names></name><name><surname>Ghebremedhin</surname><given-names>E</given-names></name><name><surname>Del Tredici</surname><given-names>K</given-names></name></person-group><article-title>Stages of the pathological process in Alzheimer&#x02019;s disease: age categories 1&#x000a0;year to 100 years</article-title><source>J Neuropathol Exp Neurol</source><year>2011</year><volume>70</volume><fpage>960</fpage><lpage>969</lpage><pub-id pub-id-type="doi">10.1097/NEN.0b013e318232a379</pub-id><pub-id pub-id-type="pmid">22002422</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brettschneider</surname><given-names>J</given-names></name><name><surname>Del Tredici</surname><given-names>K</given-names></name><name><surname>Irwin</surname><given-names>DJ</given-names></name><name><surname>Grossman</surname><given-names>M</given-names></name><name><surname>Robinson</surname><given-names>JL</given-names></name><name><surname>Toledo</surname><given-names>JB</given-names></name><name><surname>Fang</surname><given-names>L</given-names></name><name><surname>Van Deerlin</surname><given-names>VM</given-names></name><name><surname>Ludolph</surname><given-names>AC</given-names></name><name><surname>Lee</surname><given-names>VM</given-names></name><etal/></person-group><article-title>Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD)</article-title><source>Acta Neuropathol</source><year>2014</year><volume>127</volume><fpage>423</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1007/s00401-013-1238-y</pub-id><pub-id pub-id-type="pmid">24407427</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brettschneider</surname><given-names>J</given-names></name><name><surname>Del Tredici</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>VM</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name></person-group><article-title>Spreading of pathology in neurodegenerative diseases: a focus on human studies</article-title><source>Nat Rev Neurosci</source><year>2015</year><volume>16</volume><fpage>109</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1038/nrn3887</pub-id><pub-id pub-id-type="pmid">25588378</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brettschneider</surname><given-names>J</given-names></name><name><surname>Del Tredici</surname><given-names>K</given-names></name><name><surname>Toledo</surname><given-names>JB</given-names></name><name><surname>Robinson</surname><given-names>JL</given-names></name><name><surname>Irwin</surname><given-names>DJ</given-names></name><name><surname>Grossman</surname><given-names>M</given-names></name><name><surname>Suh</surname><given-names>E</given-names></name><name><surname>Van Deerlin</surname><given-names>VM</given-names></name><name><surname>Wood</surname><given-names>EM</given-names></name><name><surname>Baek</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Stages of pTDP-43 pathology in amyotrophic lateral sclerosis</article-title><source>Ann Neurol</source><year>2013</year><volume>74</volume><fpage>20</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1002/ana.23937</pub-id><pub-id pub-id-type="pmid">23686809</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cacace</surname><given-names>R</given-names></name><name><surname>Van Cauwenberghe</surname><given-names>C</given-names></name><name><surname>Bettens</surname><given-names>K</given-names></name><name><surname>Gijselinck</surname><given-names>I</given-names></name><name><surname>van der Zee</surname><given-names>J</given-names></name><name><surname>Engelborghs</surname><given-names>S</given-names></name><name><surname>Vandenbulcke</surname><given-names>M</given-names></name><name><surname>Van Dongen</surname><given-names>J</given-names></name><name><surname>Baumer</surname><given-names>V</given-names></name><name><surname>Dillen</surname><given-names>L</given-names></name><etal/></person-group><article-title>C9orf72 G4C2 repeat expansions in Alzheimer&#x02019;s disease and mild cognitive impairment</article-title><source>Neurobiol Aging</source><year>2013</year><volume>34</volume><issue>1712</issue><fpage>e1711</fpage><lpage>e1717</lpage></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cerami</surname><given-names>C</given-names></name><name><surname>Marcone</surname><given-names>A</given-names></name><name><surname>Galimberti</surname><given-names>D</given-names></name><name><surname>Zamboni</surname><given-names>M</given-names></name><name><surname>Fenoglio</surname><given-names>C</given-names></name><name><surname>Serpente</surname><given-names>M</given-names></name><name><surname>Scarpini</surname><given-names>E</given-names></name><name><surname>Cappa</surname><given-names>SF</given-names></name></person-group><article-title>Novel evidence of phenotypical variability in the hexanucleotide repeat expansion in chromosome 9</article-title><source>J Alzheimers Dis</source><year>2013</year><volume>35</volume><fpage>455</fpage><lpage>462</lpage><pub-id pub-id-type="pmid">23435409</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>YH</given-names></name><name><surname>Hebisch</surname><given-names>M</given-names></name><name><surname>Sliwinski</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>D&#x02019;Avanzo</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Hooli</surname><given-names>B</given-names></name><name><surname>Asselin</surname><given-names>C</given-names></name><name><surname>Muffat</surname><given-names>J</given-names></name><etal/></person-group><article-title>A three-dimensional human neural cell culture model of Alzheimer&#x02019;s disease</article-title><source>Nature</source><year>2014</year><volume>515</volume><fpage>274</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1038/nature13800</pub-id><pub-id pub-id-type="pmid">25307057</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clavaguera</surname><given-names>F</given-names></name><name><surname>Akatsu</surname><given-names>H</given-names></name><name><surname>Fraser</surname><given-names>G</given-names></name><name><surname>Crowther</surname><given-names>RA</given-names></name><name><surname>Frank</surname><given-names>S</given-names></name><name><surname>Hench</surname><given-names>J</given-names></name><name><surname>Probst</surname><given-names>A</given-names></name><name><surname>Winkler</surname><given-names>DT</given-names></name><name><surname>Reichwald</surname><given-names>J</given-names></name><name><surname>Staufenbiel</surname><given-names>M</given-names></name><etal/></person-group><article-title>Brain homogenates from human tauopathies induce tau inclusions in mouse brain</article-title><source>Proc Natl Acad Sci USA</source><year>2013</year><volume>110</volume><fpage>9535</fpage><lpage>9540</lpage><pub-id pub-id-type="doi">10.1073/pnas.1301175110</pub-id><pub-id pub-id-type="pmid">23690619</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clinton</surname><given-names>LK</given-names></name><name><surname>Blurton-Jones</surname><given-names>M</given-names></name><name><surname>Myczek</surname><given-names>K</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>LaFerla</surname><given-names>FM</given-names></name></person-group><article-title>Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline</article-title><source>J Neurosci</source><year>2010</year><volume>30</volume><fpage>7281</fpage><lpage>7289</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0490-10.2010</pub-id><pub-id pub-id-type="pmid">20505094</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colom-Cadena</surname><given-names>M</given-names></name><name><surname>Gelpi</surname><given-names>E</given-names></name><name><surname>Charif</surname><given-names>S</given-names></name><name><surname>Belbin</surname><given-names>O</given-names></name><name><surname>Blesa</surname><given-names>R</given-names></name><name><surname>Marti</surname><given-names>MJ</given-names></name><name><surname>Clarimon</surname><given-names>J</given-names></name><name><surname>Lleo</surname><given-names>A</given-names></name></person-group><article-title>Confluence of alpha-synuclein, tau, and beta-amyloid pathologies in dementia with Lewy bodies</article-title><source>J Neuropathol Exp Neurol</source><year>2013</year><volume>72</volume><fpage>1203</fpage><lpage>1212</lpage><pub-id pub-id-type="doi">10.1097/NEN.0000000000000018</pub-id><pub-id pub-id-type="pmid">24226269</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colom-Cadena</surname><given-names>M</given-names></name><name><surname>Gelpi</surname><given-names>E</given-names></name><name><surname>Marti</surname><given-names>MJ</given-names></name><name><surname>Charif</surname><given-names>S</given-names></name><name><surname>Dols-Icardo</surname><given-names>O</given-names></name><name><surname>Blesa</surname><given-names>R</given-names></name><name><surname>Clarimon</surname><given-names>J</given-names></name><name><surname>Lleo</surname><given-names>A</given-names></name></person-group><article-title>MAPT H1 haplotype is associated with enhanced alpha-synuclein deposition in dementia with Lewy bodies</article-title><source>Neurobiol Aging</source><year>2013</year><volume>34</volume><fpage>936</fpage><lpage>942</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2012.06.015</pub-id><pub-id pub-id-type="pmid">22819391</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Compta</surname><given-names>Y</given-names></name><name><surname>Parkkinen</surname><given-names>L</given-names></name><name><surname>O&#x02019;Sullivan</surname><given-names>SS</given-names></name><name><surname>Vandrovcova</surname><given-names>J</given-names></name><name><surname>Holton</surname><given-names>JL</given-names></name><name><surname>Collins</surname><given-names>C</given-names></name><name><surname>Lashley</surname><given-names>T</given-names></name><name><surname>Kallis</surname><given-names>C</given-names></name><name><surname>Williams</surname><given-names>DR</given-names></name><name><surname>de Silva</surname><given-names>R</given-names></name><etal/></person-group><article-title>Lewy- and Alzheimer-type pathologies in Parkinson&#x02019;s disease dementia: which is more important?</article-title><source>Brain</source><year>2011</year><volume>134</volume><fpage>1493</fpage><lpage>1505</lpage><pub-id pub-id-type="doi">10.1093/brain/awr031</pub-id><pub-id pub-id-type="pmid">21596773</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coppola</surname><given-names>G</given-names></name><name><surname>Chinnathambi</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>JJY</given-names></name></person-group><article-title>Evidence for a role of the rare p. A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer&#x02019;s diseases</article-title><source>Hum Mol Genet</source><year>2012</year><volume>21</volume><fpage>3500</fpage><lpage>3512</lpage><pub-id pub-id-type="doi">10.1093/hmg/dds161</pub-id><pub-id pub-id-type="pmid">22556362</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crary</surname><given-names>JF</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Schneider</surname><given-names>JA</given-names></name><name><surname>Abisambra</surname><given-names>JF</given-names></name><name><surname>Abner</surname><given-names>EL</given-names></name><name><surname>Alafuzoff</surname><given-names>I</given-names></name><name><surname>Arnold</surname><given-names>SE</given-names></name><name><surname>Attems</surname><given-names>J</given-names></name><name><surname>Beach</surname><given-names>TG</given-names></name><name><surname>Bigio</surname><given-names>EH</given-names></name><etal/></person-group><article-title>Primary age-related tauopathy (PART): a common pathology associated with human aging</article-title><source>Acta Neuropathol</source><year>2014</year><volume>128</volume><fpage>755</fpage><lpage>766</lpage><pub-id pub-id-type="doi">10.1007/s00401-014-1349-0</pub-id><pub-id pub-id-type="pmid">25348064</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crook</surname><given-names>R</given-names></name><name><surname>Ellis</surname><given-names>R</given-names></name><name><surname>Shanks</surname><given-names>M</given-names></name><name><surname>Thal</surname><given-names>LJ</given-names></name><name><surname>Perez-Tur</surname><given-names>J</given-names></name><name><surname>Baker</surname><given-names>M</given-names></name><name><surname>Hutton</surname><given-names>M</given-names></name><name><surname>Haltia</surname><given-names>T</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Galasko</surname><given-names>D</given-names></name></person-group><article-title>Early-onset Alzheimer&#x02019;s disease with a presenilin-1 mutation at the site corresponding to the Volga German presenilin-2 mutation</article-title><source>Ann Neurol</source><year>1997</year><volume>42</volume><fpage>124</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1002/ana.410420121</pub-id><pub-id pub-id-type="pmid">9225696</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>YS</given-names></name><name><surname>Raby</surname><given-names>S</given-names></name><name><surname>Foulds</surname><given-names>PG</given-names></name><name><surname>Robinson</surname><given-names>A</given-names></name><name><surname>Thompson</surname><given-names>JC</given-names></name><name><surname>Sikkink</surname><given-names>S</given-names></name><name><surname>Yusuf</surname><given-names>I</given-names></name><name><surname>Amin</surname><given-names>H</given-names></name><name><surname>DuPlessis</surname><given-names>D</given-names></name><name><surname>Troakes</surname><given-names>C</given-names></name><etal/></person-group><article-title>TDP-43 pathological changes in early onset familial and sporadic Alzheimer&#x02019;s disease, late onset Alzheimer&#x02019;s disease and Down&#x02019;s syndrome: association with age, hippocampal sclerosis and clinical phenotype</article-title><source>Acta Neuropathol</source><year>2011</year><volume>122</volume><fpage>703</fpage><lpage>713</lpage><pub-id pub-id-type="doi">10.1007/s00401-011-0879-y</pub-id><pub-id pub-id-type="pmid">21968532</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeJesus-Hernandez</surname><given-names>M</given-names></name><name><surname>Mackenzie</surname><given-names>IR</given-names></name><name><surname>Boeve</surname><given-names>BF</given-names></name><name><surname>Boxer</surname><given-names>AL</given-names></name><name><surname>Baker</surname><given-names>M</given-names></name><name><surname>Rutherford</surname><given-names>NJ</given-names></name><name><surname>Nicholson</surname><given-names>AM</given-names></name><name><surname>Finch</surname><given-names>NA</given-names></name><name><surname>Flynn</surname><given-names>H</given-names></name><name><surname>Adamson</surname><given-names>J</given-names></name><etal/></person-group><article-title>Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS</article-title><source>Neuron</source><year>2011</year><volume>72</volume><fpage>245</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2011.09.011</pub-id><pub-id pub-id-type="pmid">21944778</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dickson</surname><given-names>DW</given-names></name></person-group><article-title>The pathogenesis of senile plaques</article-title><source>J Neuropathol Exp Neurol</source><year>1997</year><volume>56</volume><fpage>321</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1097/00005072-199704000-00001</pub-id><pub-id pub-id-type="pmid">9100663</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dickson</surname><given-names>DW</given-names></name><name><surname>Kouri</surname><given-names>N</given-names></name><name><surname>Murray</surname><given-names>ME</given-names></name><name><surname>Josephs</surname><given-names>KA</given-names></name></person-group><article-title>Neuropathology of frontotemporal lobar degeneration-tau (FTLD-tau)</article-title><source>J Mol Neurosci</source><year>2011</year><volume>45</volume><fpage>384</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1007/s12031-011-9589-0</pub-id><pub-id pub-id-type="pmid">21720721</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dickson</surname><given-names>DW</given-names></name><name><surname>Ksiezak-Reding</surname><given-names>H</given-names></name><name><surname>Davies</surname><given-names>P</given-names></name><name><surname>Yen</surname><given-names>SH</given-names></name></person-group><article-title>A monoclonal antibody that recognizes a phosphorylated epitope in Alzheimer neurofibrillary tangles, neurofilaments and tau proteins immunostains granulovacuolar degeneration</article-title><source>Acta Neuropathol</source><year>1987</year><volume>73</volume><fpage>254</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1007/BF00686619</pub-id><pub-id pub-id-type="pmid">2441560</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Escobar-Khondiker</surname><given-names>M</given-names></name><name><surname>Hollerhage</surname><given-names>M</given-names></name><name><surname>Muriel</surname><given-names>MP</given-names></name><name><surname>Champy</surname><given-names>P</given-names></name><name><surname>Bach</surname><given-names>A</given-names></name><name><surname>Depienne</surname><given-names>C</given-names></name><name><surname>Respondek</surname><given-names>G</given-names></name><name><surname>Yamada</surname><given-names>ES</given-names></name><name><surname>Lannuzel</surname><given-names>A</given-names></name><name><surname>Yagi</surname><given-names>T</given-names></name><etal/></person-group><article-title>Annonacin, a natural mitochondrial complex I inhibitor, causes tau pathology in cultured neurons</article-title><source>J Neurosci</source><year>2007</year><volume>27</volume><fpage>7827</fpage><lpage>7837</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1644-07.2007</pub-id><pub-id pub-id-type="pmid">17634376</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esposito</surname><given-names>A</given-names></name><name><surname>Dohm</surname><given-names>CP</given-names></name><name><surname>Kermer</surname><given-names>P</given-names></name><name><surname>Bahr</surname><given-names>M</given-names></name><name><surname>Wouters</surname><given-names>FS</given-names></name></person-group><article-title>alpha-Synuclein and its disease-related mutants interact differentially with the microtubule protein tau and associate with the actin cytoskeleton</article-title><source>Neurobiol Dis</source><year>2007</year><volume>26</volume><fpage>521</fpage><lpage>531</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2007.01.014</pub-id><pub-id pub-id-type="pmid">17408955</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falcon</surname><given-names>B</given-names></name><name><surname>Cavallini</surname><given-names>A</given-names></name><name><surname>Angers</surname><given-names>R</given-names></name><name><surname>Glover</surname><given-names>S</given-names></name><name><surname>Murray</surname><given-names>TK</given-names></name><name><surname>Barnham</surname><given-names>L</given-names></name><name><surname>Jackson</surname><given-names>S</given-names></name><name><surname>O&#x02019;Neill</surname><given-names>MJ</given-names></name><name><surname>Isaacs</surname><given-names>AM</given-names></name><name><surname>Hutton</surname><given-names>ML</given-names></name><etal/></person-group><article-title>Conformation determines the seeding potencies of native and recombinant Tau aggregates</article-title><source>J Biol Chem</source><year>2015</year><volume>290</volume><fpage>1049</fpage><lpage>1065</lpage><pub-id pub-id-type="doi">10.1074/jbc.M114.589309</pub-id><pub-id pub-id-type="pmid">25406315</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujiwara</surname><given-names>H</given-names></name><name><surname>Hasegawa</surname><given-names>M</given-names></name><name><surname>Dohmae</surname><given-names>N</given-names></name><name><surname>Kawashima</surname><given-names>A</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><name><surname>Goldberg</surname><given-names>MS</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Takio</surname><given-names>K</given-names></name><name><surname>Iwatsubo</surname><given-names>T</given-names></name></person-group><article-title>alpha-Synuclein is phosphorylated in synucleinopathy lesions</article-title><source>Nat Cell Biol</source><year>2002</year><volume>4</volume><fpage>160</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1038/ncb841</pub-id><pub-id pub-id-type="pmid">11813001</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Games</surname><given-names>D</given-names></name><name><surname>Adams</surname><given-names>D</given-names></name><name><surname>Alessandrini</surname><given-names>R</given-names></name><name><surname>Barbour</surname><given-names>R</given-names></name><name><surname>Berthelette</surname><given-names>P</given-names></name><name><surname>Blackwell</surname><given-names>C</given-names></name><name><surname>Carr</surname><given-names>T</given-names></name><name><surname>Clemens</surname><given-names>J</given-names></name><name><surname>Donaldson</surname><given-names>T</given-names></name><name><surname>Gillespie</surname><given-names>F</given-names></name><etal/></person-group><article-title>Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein</article-title><source>Nature</source><year>1995</year><volume>373</volume><fpage>523</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1038/373523a0</pub-id><pub-id pub-id-type="pmid">7845465</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghetti</surname><given-names>B</given-names></name><name><surname>Oblak</surname><given-names>AL</given-names></name><name><surname>Boeve</surname><given-names>BF</given-names></name><name><surname>Johnson</surname><given-names>KA</given-names></name><name><surname>Dickerson</surname><given-names>BC</given-names></name><name><surname>Goedert</surname><given-names>M</given-names></name></person-group><article-title>Invited review: frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: a chameleon for neuropathology and neuroimaging</article-title><source>Neuropathol Appl Neurobiol</source><year>2015</year><volume>41</volume><fpage>24</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1111/nan.12213</pub-id><pub-id pub-id-type="pmid">25556536</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giasson</surname><given-names>BI</given-names></name><name><surname>Forman</surname><given-names>MS</given-names></name><name><surname>Higuchi</surname><given-names>M</given-names></name><name><surname>Golbe</surname><given-names>LI</given-names></name><name><surname>Graves</surname><given-names>CL</given-names></name><name><surname>Kotzbauer</surname><given-names>PT</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Lee</surname><given-names>VM</given-names></name></person-group><article-title>Initiation and synergistic fibrillization of tau and alpha-synuclein</article-title><source>Science</source><year>2003</year><volume>300</volume><fpage>636</fpage><lpage>640</lpage><pub-id pub-id-type="doi">10.1126/science.1082324</pub-id><pub-id pub-id-type="pmid">12714745</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goate</surname><given-names>A</given-names></name><name><surname>Chartier-Harlin</surname><given-names>MC</given-names></name><name><surname>Mullan</surname><given-names>M</given-names></name><name><surname>Brown</surname><given-names>J</given-names></name><name><surname>Crawford</surname><given-names>F</given-names></name><name><surname>Fidani</surname><given-names>L</given-names></name><name><surname>Giuffra</surname><given-names>L</given-names></name><name><surname>Haynes</surname><given-names>A</given-names></name><name><surname>Irving</surname><given-names>N</given-names></name><name><surname>James</surname><given-names>L</given-names></name><etal/></person-group><article-title>Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer&#x02019;s disease</article-title><source>Nature</source><year>1991</year><volume>349</volume><fpage>704</fpage><lpage>706</lpage><pub-id pub-id-type="doi">10.1038/349704a0</pub-id><pub-id pub-id-type="pmid">1671712</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goedert</surname><given-names>M</given-names></name></person-group><article-title>NEURODEGENERATION. Alzheimer&#x02019;s and Parkinson&#x02019;s diseases: the prion concept in relation to assembled A&#x003b2;, tau, and &#x003b1;-synuclein</article-title><source>Science</source><year>2015</year><volume>349</volume><fpage>1255555</fpage><pub-id pub-id-type="doi">10.1126/science.1255555</pub-id><pub-id pub-id-type="pmid">26250687</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goedert</surname><given-names>M</given-names></name><name><surname>Spillantini</surname><given-names>MG</given-names></name><name><surname>Jakes</surname><given-names>R</given-names></name><name><surname>Rutherford</surname><given-names>D</given-names></name><name><surname>Crowther</surname><given-names>RA</given-names></name></person-group><article-title>Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer&#x02019;s disease</article-title><source>Neuron</source><year>1989</year><volume>3</volume><fpage>519</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1016/0896-6273(89)90210-9</pub-id><pub-id pub-id-type="pmid">2484340</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomez-Isla</surname><given-names>T</given-names></name><name><surname>Price</surname><given-names>JL</given-names></name><name><surname>McKeel</surname><given-names>DW</given-names><suffix>Jr</suffix></name><name><surname>Morris</surname><given-names>JC</given-names></name><name><surname>Growdon</surname><given-names>JH</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name></person-group><article-title>Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer&#x02019;s disease</article-title><source>J Neurosci</source><year>1996</year><volume>16</volume><fpage>4491</fpage><lpage>4500</lpage><pub-id pub-id-type="pmid">8699259</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomperts</surname><given-names>SN</given-names></name></person-group><article-title>Imaging the role of amyloid in PD dementia and dementia with Lewy bodies</article-title><source>Curr Neurol Neurosci Rep</source><year>2014</year><volume>14</volume><fpage>472</fpage><pub-id pub-id-type="doi">10.1007/s11910-014-0472-6</pub-id><pub-id pub-id-type="pmid">25011528</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomperts</surname><given-names>SN</given-names></name><name><surname>Locascio</surname><given-names>JJ</given-names></name><name><surname>Makaretz</surname><given-names>SJ</given-names></name><name><surname>Schultz</surname><given-names>A</given-names></name><name><surname>Caso</surname><given-names>C</given-names></name><name><surname>Vasdev</surname><given-names>N</given-names></name><name><surname>Sperling</surname><given-names>R</given-names></name><name><surname>Growdon</surname><given-names>JH</given-names></name><name><surname>Dickerson</surname><given-names>BC</given-names></name><name><surname>Johnson</surname><given-names>K</given-names></name></person-group><article-title>Tau positron emission tomographic imaging in the Lewy body diseases</article-title><source>JAMA Neurol</source><year>2016</year><volume>73</volume><fpage>1334</fpage><lpage>1341</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2016.3338</pub-id><pub-id pub-id-type="pmid">27654968</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grundke-Iqbal</surname><given-names>I</given-names></name><name><surname>Iqbal</surname><given-names>K</given-names></name><name><surname>Quinlan</surname><given-names>M</given-names></name><name><surname>Tung</surname><given-names>YC</given-names></name><name><surname>Zaidi</surname><given-names>MS</given-names></name><name><surname>Wisniewski</surname><given-names>HM</given-names></name></person-group><article-title>Microtubule-associated protein tau. A component of Alzheimer paired helical filaments</article-title><source>J Biol Chem</source><year>1986</year><volume>261</volume><fpage>6084</fpage><lpage>6089</lpage><pub-id pub-id-type="pmid">3084478</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>J-P</given-names></name><name><surname>Arai</surname><given-names>T</given-names></name><name><surname>Miklossy</surname><given-names>J</given-names></name><name><surname>McGeer</surname><given-names>PL</given-names></name></person-group><article-title>A&#x003b2; and tau form soluble complexes that may promote self aggregation of both into the insoluble forms observed in Alzheimer&#x02019;s disease</article-title><source>Proc Natl Acad Sci USA</source><year>2006</year><volume>103</volume><fpage>1953</fpage><lpage>1958</lpage><pub-id pub-id-type="doi">10.1073/pnas.0509386103</pub-id><pub-id pub-id-type="pmid">16446437</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>JL</given-names></name><name><surname>Covell</surname><given-names>DJ</given-names></name><name><surname>Daniels</surname><given-names>JP</given-names></name><name><surname>Iba</surname><given-names>M</given-names></name><name><surname>Stieber</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Riddle</surname><given-names>DM</given-names></name><name><surname>Kwong</surname><given-names>LK</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><etal/></person-group><article-title>Distinct &#x003b1;-synuclein strains differentially promote tau inclusions in neurons</article-title><source>Cell</source><year>2013</year><volume>154</volume><fpage>103</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.05.057</pub-id><pub-id pub-id-type="pmid">23827677</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haggerty</surname><given-names>T</given-names></name><name><surname>Credle</surname><given-names>J</given-names></name><name><surname>Rodriguez</surname><given-names>O</given-names></name><name><surname>Wills</surname><given-names>J</given-names></name><name><surname>Oaks</surname><given-names>AW</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><name><surname>Sidhu</surname><given-names>A</given-names></name></person-group><article-title>Hyperphosphorylated Tau in an alpha-synuclein-overexpressing transgenic model of Parkinson&#x02019;s disease</article-title><source>Eur J Neurosci</source><year>2011</year><volume>33</volume><fpage>1598</fpage><lpage>1610</lpage><pub-id pub-id-type="doi">10.1111/j.1460-9568.2011.07660.x</pub-id><pub-id pub-id-type="pmid">21453448</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hardy</surname><given-names>J</given-names></name></person-group><article-title>Genetic analysis of pathways to Parkinson disease</article-title><source>Neuron</source><year>2010</year><volume>68</volume><fpage>201</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2010.10.014</pub-id><pub-id pub-id-type="pmid">20955928</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name></person-group><article-title>The amyloid hypothesis of Alzheimer&#x02019;s disease: progress and problems on the road to therapeutics</article-title><source>Science</source><year>2002</year><volume>297</volume><fpage>353</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1126/science.1072994</pub-id><pub-id pub-id-type="pmid">12130773</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harms</surname><given-names>M</given-names></name><name><surname>Benitez</surname><given-names>BA</given-names></name><name><surname>Cairns</surname><given-names>N</given-names></name><name><surname>Cooper</surname><given-names>B</given-names></name><name><surname>Cooper</surname><given-names>P</given-names></name><name><surname>Mayo</surname><given-names>K</given-names></name><name><surname>Carrell</surname><given-names>D</given-names></name><name><surname>Faber</surname><given-names>K</given-names></name><name><surname>Williamson</surname><given-names>J</given-names></name><name><surname>Bird</surname><given-names>T</given-names></name><etal/></person-group><article-title>C9orf72 hexanucleotide repeat expansions in clinical Alzheimer disease</article-title><source>JAMA Neurol</source><year>2013</year><volume>70</volume><fpage>736</fpage><lpage>741</lpage><pub-id pub-id-type="doi">10.1001/2013.jamaneurol.537</pub-id><pub-id pub-id-type="pmid">23588422</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holmes</surname><given-names>BB</given-names></name><name><surname>Furman</surname><given-names>JL</given-names></name><name><surname>Mahan</surname><given-names>TE</given-names></name><name><surname>Yamasaki</surname><given-names>TR</given-names></name><name><surname>Mirbaha</surname><given-names>H</given-names></name><name><surname>Eades</surname><given-names>WC</given-names></name><name><surname>Belaygorod</surname><given-names>L</given-names></name><name><surname>Cairns</surname><given-names>NJ</given-names></name><name><surname>Holtzman</surname><given-names>DM</given-names></name><name><surname>Diamond</surname><given-names>MI</given-names></name></person-group><article-title>Proteopathic tau seeding predicts tauopathy in vivo</article-title><source>Proc Natl Acad Sci USA</source><year>2014</year><volume>111</volume><fpage>85</fpage><pub-id pub-id-type="doi">10.1073/pnas.1419827111</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsiao</surname><given-names>K</given-names></name><name><surname>Chapman</surname><given-names>P</given-names></name><name><surname>Nilsen</surname><given-names>S</given-names></name><name><surname>Eckman</surname><given-names>C</given-names></name><name><surname>Harigaya</surname><given-names>Y</given-names></name><name><surname>Younkin</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Cole</surname><given-names>G</given-names></name></person-group><article-title>Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice</article-title><source>Science</source><year>1996</year><volume>274</volume><fpage>99</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1126/science.274.5284.99</pub-id><pub-id pub-id-type="pmid">8810256</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>NW</given-names></name><name><surname>Nicoll</surname><given-names>AJ</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Mably</surname><given-names>AJ</given-names></name><name><surname>O&#x02019;Malley</surname><given-names>T</given-names></name><name><surname>Purro</surname><given-names>SA</given-names></name><name><surname>Terry</surname><given-names>C</given-names></name><name><surname>Collinge</surname><given-names>J</given-names></name><name><surname>Walsh</surname><given-names>DM</given-names></name><name><surname>Rowan</surname><given-names>MJ</given-names></name></person-group><article-title>mGlu5 receptors and cellular prion protein mediate amyloid-beta-facilitated synaptic long-term depression in vivo</article-title><source>Nat Commun</source><year>2014</year><volume>5</volume><fpage>3374</fpage><pub-id pub-id-type="pmid">24594908</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hubbers</surname><given-names>CU</given-names></name><name><surname>Clemen</surname><given-names>CS</given-names></name><name><surname>Kesper</surname><given-names>K</given-names></name><name><surname>Boddrich</surname><given-names>A</given-names></name><name><surname>Hofmann</surname><given-names>A</given-names></name><name><surname>Kamarainen</surname><given-names>O</given-names></name><name><surname>Tolksdorf</surname><given-names>K</given-names></name><name><surname>Stumpf</surname><given-names>M</given-names></name><name><surname>Reichelt</surname><given-names>J</given-names></name><name><surname>Roth</surname><given-names>U</given-names></name><etal/></person-group><article-title>Pathological consequences of VCP mutations on human striated muscle</article-title><source>Brain</source><year>2007</year><volume>130</volume><fpage>381</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.1093/brain/awl238</pub-id><pub-id pub-id-type="pmid">16984901</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hutton</surname><given-names>M</given-names></name><name><surname>Lendon</surname><given-names>CL</given-names></name><name><surname>Rizzu</surname><given-names>P</given-names></name><name><surname>Baker</surname><given-names>M</given-names></name><name><surname>Froelich</surname><given-names>S</given-names></name><name><surname>Houlden</surname><given-names>H</given-names></name><name><surname>Pickering-Brown</surname><given-names>S</given-names></name><name><surname>Chakraverty</surname><given-names>S</given-names></name><name><surname>Isaacs</surname><given-names>A</given-names></name><name><surname>Grover</surname><given-names>A</given-names></name><etal/></person-group><article-title>Association of missense and 5&#x02032;-splice-site mutations in tau with the inherited dementia FTDP-17</article-title><source>Nature</source><year>1998</year><volume>393</volume><fpage>702</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1038/31508</pub-id><pub-id pub-id-type="pmid">9641683</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hyman</surname><given-names>BT</given-names></name><name><surname>Phelps</surname><given-names>CH</given-names></name><name><surname>Beach</surname><given-names>TG</given-names></name><name><surname>Bigio</surname><given-names>EH</given-names></name><name><surname>Cairns</surname><given-names>NJ</given-names></name><name><surname>Carrillo</surname><given-names>MC</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name><name><surname>Duyckaerts</surname><given-names>C</given-names></name><name><surname>Frosch</surname><given-names>MP</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><etal/></person-group><article-title>National Institute on Aging&#x02013;Alzheimer&#x02019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x02019;s disease</article-title><source>Alzheimers Dement</source><year>2012</year><volume>8</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2011.10.007</pub-id><pub-id pub-id-type="pmid">22265587</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irwin</surname><given-names>DJ</given-names></name><name><surname>Grossman</surname><given-names>M</given-names></name><name><surname>Weintraub</surname><given-names>D</given-names></name><name><surname>Hurtig</surname><given-names>HI</given-names></name><name><surname>Duda</surname><given-names>JE</given-names></name><name><surname>Xie</surname><given-names>SX</given-names></name><name><surname>Lee</surname><given-names>EB</given-names></name><name><surname>Van Deerlin</surname><given-names>VM</given-names></name><name><surname>Lopez</surname><given-names>OL</given-names></name><name><surname>Kofler</surname><given-names>JK</given-names></name><etal/></person-group><article-title>Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis</article-title><source>Lancet Neurol</source><year>2017</year><volume>16</volume><fpage>55</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(16)30291-5</pub-id><pub-id pub-id-type="pmid">27979356</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishizawa</surname><given-names>T</given-names></name><name><surname>Mattila</surname><given-names>P</given-names></name><name><surname>Davies</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name></person-group><article-title>Colocalization of tau and alpha-synuclein epitopes in Lewy bodies</article-title><source>J Neuropathol Exp Neurol</source><year>2003</year><volume>62</volume><fpage>389</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1093/jnen/62.4.389</pub-id><pub-id pub-id-type="pmid">12722831</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ittner</surname><given-names>LM</given-names></name><name><surname>Ke</surname><given-names>YD</given-names></name><name><surname>Delerue</surname><given-names>F</given-names></name><name><surname>Bi</surname><given-names>M</given-names></name><name><surname>Gladbach</surname><given-names>A</given-names></name><name><surname>van Eersel</surname><given-names>J</given-names></name><name><surname>W&#x000f6;lfing</surname><given-names>H</given-names></name><name><surname>Chieng</surname><given-names>BC</given-names></name><name><surname>Christie</surname><given-names>MJ</given-names></name><name><surname>Napier</surname><given-names>IA</given-names></name><name><surname>Eckert</surname><given-names>A</given-names></name><name><surname>Staufenbiel</surname><given-names>M</given-names></name><name><surname>Hardeman</surname><given-names>E</given-names></name><name><surname>G&#x000f6;tz</surname><given-names>J</given-names></name></person-group><article-title>Dendritic function of tau mediates amyloid-&#x003b2; toxicity in Alzheimer&#x02019;s disease mouse models</article-title><source>Cell</source><year>2010</year><volume>142</volume><fpage>387</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2010.06.036</pub-id><pub-id pub-id-type="pmid">20655099</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></name></person-group><article-title>PART and SNAP</article-title><source>Acta Neuropathol</source><year>2014</year><volume>128</volume><fpage>773</fpage><lpage>776</lpage><pub-id pub-id-type="doi">10.1007/s00401-014-1362-3</pub-id><pub-id pub-id-type="pmid">25380757</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>RJ</given-names></name><name><surname>Rudinskiy</surname><given-names>N</given-names></name><name><surname>Herrmann</surname><given-names>AG</given-names></name><name><surname>Croft</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>JSM</given-names></name><name><surname>Petrova</surname><given-names>V</given-names></name><name><surname>Ramos-Rodriguez</surname><given-names>JJ</given-names></name><name><surname>Pitstick</surname><given-names>R</given-names></name><name><surname>Wegmann</surname><given-names>S</given-names></name><name><surname>Garcia-Alloza</surname><given-names>M</given-names></name><etal/></person-group><article-title>Human tau increases amyloid &#x003b2; plaque size but not amyloid &#x003b2;-mediated synapse loss in a novel mouse model of Alzheimer&#x02019;s disease</article-title><source>Eur J Neurosci</source><year>2016</year><volume>44</volume><fpage>3056</fpage><lpage>3066</lpage><pub-id pub-id-type="doi">10.1111/ejn.13442</pub-id><pub-id pub-id-type="pmid">27748574</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jellinger</surname><given-names>KA</given-names></name><name><surname>Attems</surname><given-names>J</given-names></name></person-group><article-title>Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies?</article-title><source>Acta Neuropathol</source><year>2006</year><volume>112</volume><fpage>253</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1007/s00401-006-0088-2</pub-id><pub-id pub-id-type="pmid">16804711</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jellinger</surname><given-names>KA</given-names></name><name><surname>Attems</surname><given-names>J</given-names></name></person-group><article-title>Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease</article-title><source>Acta Neuropathol</source><year>2008</year><volume>115</volume><fpage>427</fpage><lpage>436</lpage><pub-id pub-id-type="doi">10.1007/s00401-008-0347-5</pub-id><pub-id pub-id-type="pmid">18273624</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>PH</given-names></name><name><surname>Hager</surname><given-names>H</given-names></name><name><surname>Nielsen</surname><given-names>MS</given-names></name><name><surname>Hojrup</surname><given-names>P</given-names></name><name><surname>Gliemann</surname><given-names>J</given-names></name><name><surname>Jakes</surname><given-names>R</given-names></name></person-group><article-title>alpha-synuclein binds to Tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356</article-title><source>J Biol Chem</source><year>1999</year><volume>274</volume><fpage>25481</fpage><lpage>25489</lpage><pub-id pub-id-type="doi">10.1074/jbc.274.36.25481</pub-id><pub-id pub-id-type="pmid">10464279</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jonsson</surname><given-names>T</given-names></name><name><surname>Atwal</surname><given-names>JK</given-names></name><name><surname>Steinberg</surname><given-names>S</given-names></name><name><surname>Snaedal</surname><given-names>J</given-names></name><name><surname>Jonsson</surname><given-names>PV</given-names></name><name><surname>Bjornsson</surname><given-names>S</given-names></name><name><surname>Stefansson</surname><given-names>H</given-names></name><name><surname>Sulem</surname><given-names>P</given-names></name><name><surname>Gudbjartsson</surname><given-names>D</given-names></name><name><surname>Maloney</surname><given-names>J</given-names></name><etal/></person-group><article-title>A mutation in APP protects against Alzheimer&#x02019;s disease and age-related cognitive decline</article-title><source>Nature</source><year>2012</year><volume>488</volume><fpage>96</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1038/nature11283</pub-id><pub-id pub-id-type="pmid">22801501</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Josephs</surname><given-names>KA</given-names></name><name><surname>Murray</surname><given-names>ME</given-names></name><name><surname>Whitwell</surname><given-names>JL</given-names></name><name><surname>Parisi</surname><given-names>JE</given-names></name><name><surname>Petrucelli</surname><given-names>L</given-names></name><name><surname>Jack</surname><given-names>CR</given-names></name><name><surname>Petersen</surname><given-names>RC</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name></person-group><article-title>Staging TDP-43 pathology in Alzheimer&#x02019;s disease</article-title><source>Acta Neuropathol</source><year>2014</year><volume>127</volume><fpage>441</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.1007/s00401-013-1211-9</pub-id><pub-id pub-id-type="pmid">24240737</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Josephs</surname><given-names>KA</given-names></name><name><surname>Murray</surname><given-names>ME</given-names></name><name><surname>Whitwell</surname><given-names>JL</given-names></name><name><surname>Tosakulwong</surname><given-names>N</given-names></name><name><surname>Weigand</surname><given-names>SD</given-names></name><name><surname>Petrucelli</surname><given-names>L</given-names></name><name><surname>Liesinger</surname><given-names>AM</given-names></name><name><surname>Petersen</surname><given-names>RC</given-names></name><name><surname>Parisi</surname><given-names>JE</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name></person-group><article-title>Updated TDP-43 in Alzheimer&#x02019;s disease staging scheme</article-title><source>Acta Neuropathol</source><year>2016</year><volume>131</volume><fpage>571</fpage><lpage>585</lpage><pub-id pub-id-type="doi">10.1007/s00401-016-1537-1</pub-id><pub-id pub-id-type="pmid">26810071</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Josephs</surname><given-names>KA</given-names></name><name><surname>Whitwell</surname><given-names>JL</given-names></name><name><surname>Parisi</surname><given-names>JE</given-names></name><name><surname>Knopman</surname><given-names>DS</given-names></name><name><surname>Boeve</surname><given-names>BF</given-names></name><name><surname>Geda</surname><given-names>YE</given-names></name><name><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></name><name><surname>Petersen</surname><given-names>RC</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name></person-group><article-title>Argyrophilic grains: a distinct disease or an additive pathology?</article-title><source>Neurobiol Aging</source><year>2008</year><volume>29</volume><fpage>566</fpage><lpage>573</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2006.10.032</pub-id><pub-id pub-id-type="pmid">17188783</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jucker</surname><given-names>M</given-names></name><name><surname>Walker</surname><given-names>LC</given-names></name></person-group><article-title>Self-propagation of pathogenic protein aggregates in neurodegenerative diseases</article-title><source>Nature</source><year>2013</year><volume>501</volume><fpage>45</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1038/nature12481</pub-id><pub-id pub-id-type="pmid">24005412</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kabashi</surname><given-names>E</given-names></name><name><surname>Valdmanis</surname><given-names>PN</given-names></name><name><surname>Dion</surname><given-names>P</given-names></name><name><surname>Spiegelman</surname><given-names>D</given-names></name><name><surname>McConkey</surname><given-names>BJ</given-names></name><name><surname>Vande Velde</surname><given-names>C</given-names></name><name><surname>Bouchard</surname><given-names>JP</given-names></name><name><surname>Lacomblez</surname><given-names>L</given-names></name><name><surname>Pochigaeva</surname><given-names>K</given-names></name><name><surname>Salachas</surname><given-names>F</given-names></name><etal/></person-group><article-title>TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis</article-title><source>Nat Genet</source><year>2008</year><volume>40</volume><fpage>572</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1038/ng.132</pub-id><pub-id pub-id-type="pmid">18372902</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kadokura</surname><given-names>A</given-names></name><name><surname>Yamazaki</surname><given-names>T</given-names></name><name><surname>Kakuda</surname><given-names>S</given-names></name><name><surname>Makioka</surname><given-names>K</given-names></name><name><surname>Lemere</surname><given-names>CA</given-names></name><name><surname>Fujita</surname><given-names>Y</given-names></name><name><surname>Takatama</surname><given-names>M</given-names></name><name><surname>Okamoto</surname><given-names>K</given-names></name></person-group><article-title>Phosphorylation-dependent TDP-43 antibody detects intraneuronal dot-like structures showing morphological characters of granulovacuolar degeneration</article-title><source>Neurosci Lett</source><year>2009</year><volume>463</volume><fpage>87</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2009.06.024</pub-id><pub-id pub-id-type="pmid">19539703</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalaitzakis</surname><given-names>ME</given-names></name><name><surname>Walls</surname><given-names>AJ</given-names></name><name><surname>Pearce</surname><given-names>RK</given-names></name><name><surname>Gentleman</surname><given-names>SM</given-names></name></person-group><article-title>Striatal Abeta peptide deposition mirrors dementia and differentiates DLB and PDD from other parkinsonian syndromes</article-title><source>Neurobiol Dis</source><year>2011</year><volume>41</volume><fpage>377</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2010.10.005</pub-id><pub-id pub-id-type="pmid">20951207</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><mixed-citation publication-type="other">Kapasi A, De Carlie C, Schneider JA (2017) Impact of multiple pathologies of the threshold for clinically overt dementia. Acta Neuropathol <bold>(in press)</bold></mixed-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kay</surname><given-names>KR</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>Wright</surname><given-names>AK</given-names></name><name><surname>Serrano-Pozo</surname><given-names>A</given-names></name><name><surname>Pooler</surname><given-names>AM</given-names></name><name><surname>Koffie</surname><given-names>R</given-names></name><name><surname>Bastin</surname><given-names>ME</given-names></name><name><surname>Bak</surname><given-names>TH</given-names></name><name><surname>Abrahams</surname><given-names>S</given-names></name><name><surname>Kopeikina</surname><given-names>KJ</given-names></name><etal/></person-group><article-title>Studying synapses in human brain with array tomography and electron microscopy</article-title><source>Nat Protoc</source><year>2013</year><volume>8</volume><fpage>1366</fpage><lpage>1380</lpage><pub-id pub-id-type="doi">10.1038/nprot.2013.078</pub-id><pub-id pub-id-type="pmid">23787894</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keller</surname><given-names>BA</given-names></name><name><surname>Volkening</surname><given-names>K</given-names></name><name><surname>Droppelmann</surname><given-names>CA</given-names></name><name><surname>Ang</surname><given-names>LC</given-names></name><name><surname>Rademakers</surname><given-names>R</given-names></name><name><surname>Strong</surname><given-names>MJ</given-names></name></person-group><article-title>Co-aggregation of RNA binding proteins in ALS spinal motor neurons: evidence of a common pathogenic mechanism</article-title><source>Acta Neuropathol</source><year>2012</year><volume>124</volume><fpage>733</fpage><lpage>747</lpage><pub-id pub-id-type="doi">10.1007/s00401-012-1035-z</pub-id><pub-id pub-id-type="pmid">22941224</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Kim</surname><given-names>NC</given-names></name><name><surname>Wang</surname><given-names>YD</given-names></name><name><surname>Scarborough</surname><given-names>EA</given-names></name><name><surname>Moore</surname><given-names>J</given-names></name></person-group><article-title>Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS</article-title><source>Nature</source><year>2013</year><volume>495</volume><fpage>467</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1038/nature11922</pub-id><pub-id pub-id-type="pmid">23455423</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knowles</surname><given-names>TP</given-names></name><name><surname>Vendruscolo</surname><given-names>M</given-names></name><name><surname>Dobson</surname><given-names>CM</given-names></name></person-group><article-title>The amyloid state and its association with protein misfolding diseases</article-title><source>Nat Rev Mol Cell Biol</source><year>2014</year><volume>15</volume><issue>384</issue><fpage>396</fpage></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kokubo</surname><given-names>Y</given-names></name><name><surname>Taniguchi</surname><given-names>A</given-names></name><name><surname>Hasegawa</surname><given-names>M</given-names></name><name><surname>Hayakawa</surname><given-names>Y</given-names></name><name><surname>Morimoto</surname><given-names>S</given-names></name><name><surname>Yoneda</surname><given-names>M</given-names></name><name><surname>Hirokawa</surname><given-names>Y</given-names></name><name><surname>Shiraishi</surname><given-names>T</given-names></name><name><surname>Saito</surname><given-names>Y</given-names></name><name><surname>Murayama</surname><given-names>S</given-names></name><etal/></person-group><article-title>alpha-Synuclein pathology in the amyotrophic lateral sclerosis/parkinsonism dementia complex in the Kii Peninsula, Japan</article-title><source>J Neuropathol Exp Neurol</source><year>2012</year><volume>71</volume><fpage>625</fpage><lpage>630</lpage><pub-id pub-id-type="doi">10.1097/NEN.0b013e31825b9680</pub-id><pub-id pub-id-type="pmid">22710962</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Wirths</surname><given-names>O</given-names></name><name><surname>Stuber</surname><given-names>K</given-names></name><name><surname>Wunderlich</surname><given-names>P</given-names></name><name><surname>Koch</surname><given-names>P</given-names></name><name><surname>Theil</surname><given-names>S</given-names></name><name><surname>Rezaei-Ghaleh</surname><given-names>N</given-names></name><name><surname>Zweckstetter</surname><given-names>M</given-names></name><name><surname>Bayer</surname><given-names>TA</given-names></name><name><surname>Brustle</surname><given-names>O</given-names></name><etal/></person-group><article-title>Phosphorylation of the amyloid beta-peptide at Ser26 stabilizes oligomeric assembly and increases neurotoxicity</article-title><source>Acta Neuropathol</source><year>2016</year><volume>131</volume><fpage>525</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1007/s00401-016-1546-0</pub-id><pub-id pub-id-type="pmid">26898910</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Labbe</surname><given-names>C</given-names></name><name><surname>Ogaki</surname><given-names>K</given-names></name><name><surname>Lorenzo-Betancor</surname><given-names>O</given-names></name><name><surname>Soto-Ortolaza</surname><given-names>AI</given-names></name><name><surname>Walton</surname><given-names>RL</given-names></name><name><surname>Rayaprolu</surname><given-names>S</given-names></name><name><surname>Fujioka</surname><given-names>S</given-names></name><name><surname>Murray</surname><given-names>ME</given-names></name><name><surname>Heckman</surname><given-names>MG</given-names></name><name><surname>Puschmann</surname><given-names>A</given-names></name><etal/></person-group><article-title>Role for the microtubule-associated protein tau variant p. A152T in risk of alpha-synucleinopathies</article-title><source>Neurology</source><year>2015</year><volume>85</volume><fpage>1680</fpage><lpage>1686</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000001946</pub-id><pub-id pub-id-type="pmid">26333800</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lauren</surname><given-names>J</given-names></name><name><surname>Gimbel</surname><given-names>DA</given-names></name><name><surname>Nygaard</surname><given-names>HB</given-names></name><name><surname>Gilbert</surname><given-names>JW</given-names></name><name><surname>Strittmatter</surname><given-names>SM</given-names></name></person-group><article-title>Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers</article-title><source>Nature</source><year>2009</year><volume>457</volume><fpage>1128</fpage><lpage>1132</lpage><pub-id pub-id-type="doi">10.1038/nature07761</pub-id><pub-id pub-id-type="pmid">19242475</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>K-HH</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Mitrea</surname><given-names>DM</given-names></name><name><surname>Sarkar</surname><given-names>M</given-names></name><name><surname>Freibaum</surname><given-names>BD</given-names></name><name><surname>Cika</surname><given-names>J</given-names></name><name><surname>Coughlin</surname><given-names>M</given-names></name><name><surname>Messing</surname><given-names>J</given-names></name><name><surname>Molliex</surname><given-names>A</given-names></name><etal/></person-group><article-title>C9orf72 dipeptide repeats impair the assembly, dynamics, and function of membrane-less organelles</article-title><source>Cell</source><year>2016</year><volume>167</volume><fpage>774</fpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.10.002</pub-id><pub-id pub-id-type="pmid">27768896</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>J</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name><name><surname>Lin</surname><given-names>WL</given-names></name><name><surname>Chisholm</surname><given-names>L</given-names></name><name><surname>Corral</surname><given-names>A</given-names></name><name><surname>Jones</surname><given-names>G</given-names></name><name><surname>Yen</surname><given-names>SH</given-names></name><name><surname>Sahara</surname><given-names>N</given-names></name><name><surname>Skipper</surname><given-names>L</given-names></name><name><surname>Yager</surname><given-names>D</given-names></name><etal/></person-group><article-title>Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP</article-title><source>Science</source><year>2001</year><volume>293</volume><fpage>1487</fpage><lpage>1491</lpage><pub-id pub-id-type="doi">10.1126/science.1058189</pub-id><pub-id pub-id-type="pmid">11520987</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lippa</surname><given-names>CF</given-names></name><name><surname>Fujiwara</surname><given-names>H</given-names></name><name><surname>Mann</surname><given-names>DM</given-names></name><name><surname>Giasson</surname><given-names>B</given-names></name><name><surname>Baba</surname><given-names>M</given-names></name><name><surname>Schmidt</surname><given-names>ML</given-names></name><name><surname>Nee</surname><given-names>LE</given-names></name><name><surname>O&#x02019;Connell</surname><given-names>B</given-names></name><name><surname>Pollen</surname><given-names>DA</given-names></name><name><surname>St George-Hyslop</surname><given-names>P</given-names></name><etal/></person-group><article-title>Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer&#x02019;s disease patients with mutations in presenilin and amyloid precursor protein genes</article-title><source>Am J Pathol</source><year>1998</year><volume>153</volume><fpage>1365</fpage><lpage>1370</lpage><pub-id pub-id-type="doi">10.1016/S0002-9440(10)65722-7</pub-id><pub-id pub-id-type="pmid">9811326</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mackenzie</surname><given-names>IR</given-names></name><name><surname>Arzberger</surname><given-names>T</given-names></name><name><surname>Kremmer</surname><given-names>E</given-names></name><name><surname>Troost</surname><given-names>D</given-names></name><name><surname>Lorenzl</surname><given-names>S</given-names></name><name><surname>Mori</surname><given-names>K</given-names></name><name><surname>Weng</surname><given-names>SM</given-names></name><name><surname>Haass</surname><given-names>C</given-names></name><name><surname>Kretzschmar</surname><given-names>HA</given-names></name><name><surname>Edbauer</surname><given-names>D</given-names></name><etal/></person-group><article-title>Dipeptide repeat protein pathology in C9ORF72 mutation cases: clinico-pathological correlations</article-title><source>Acta Neuropathol</source><year>2013</year><volume>126</volume><fpage>859</fpage><lpage>879</lpage><pub-id pub-id-type="doi">10.1007/s00401-013-1181-y</pub-id><pub-id pub-id-type="pmid">24096617</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mackenzie</surname><given-names>IR</given-names></name><name><surname>Neumann</surname><given-names>M</given-names></name><name><surname>Bigio</surname><given-names>EH</given-names></name><name><surname>Cairns</surname><given-names>NJ</given-names></name><name><surname>Alafuzoff</surname><given-names>I</given-names></name><name><surname>Kril</surname><given-names>J</given-names></name><name><surname>Kovacs</surname><given-names>GG</given-names></name><name><surname>Ghetti</surname><given-names>B</given-names></name><name><surname>Halliday</surname><given-names>G</given-names></name><name><surname>Holm</surname><given-names>IE</given-names></name><etal/></person-group><article-title>Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update</article-title><source>Acta Neuropathol</source><year>2010</year><volume>119</volume><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1007/s00401-009-0612-2</pub-id><pub-id pub-id-type="pmid">19924424</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mandal</surname><given-names>PK</given-names></name><name><surname>Pettegrew</surname><given-names>JW</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><name><surname>Hamilton</surname><given-names>RL</given-names></name><name><surname>Mandal</surname><given-names>R</given-names></name></person-group><article-title>Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer&#x02019;s and Parkinson&#x02019;s in dementia with Lewy body disease</article-title><source>Neurochem Res</source><year>2006</year><volume>31</volume><fpage>1153</fpage><lpage>1162</lpage><pub-id pub-id-type="doi">10.1007/s11064-006-9140-9</pub-id><pub-id pub-id-type="pmid">16947080</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masliah</surname><given-names>E</given-names></name><name><surname>Rockenstein</surname><given-names>E</given-names></name><name><surname>Veinbergs</surname><given-names>I</given-names></name><name><surname>Sagara</surname><given-names>Y</given-names></name><name><surname>Mallory</surname><given-names>M</given-names></name><name><surname>Hashimoto</surname><given-names>M</given-names></name><name><surname>Mucke</surname><given-names>L</given-names></name></person-group><article-title>beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer&#x02019;s disease and Parkinson&#x02019;s disease</article-title><source>Proc Natl Acad Sci USA</source><year>2001</year><volume>98</volume><fpage>12245</fpage><lpage>12250</lpage><pub-id pub-id-type="doi">10.1073/pnas.211412398</pub-id><pub-id pub-id-type="pmid">11572944</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masters</surname><given-names>CL</given-names></name><name><surname>Simms</surname><given-names>G</given-names></name><name><surname>Weinman</surname><given-names>NA</given-names></name><name><surname>Multhaup</surname><given-names>G</given-names></name><name><surname>McDonald</surname><given-names>BL</given-names></name><name><surname>Beyreuther</surname><given-names>K</given-names></name></person-group><article-title>Amyloid plaque core protein in Alzheimer disease and Down syndrome</article-title><source>Proc Natl Acad Sci USA</source><year>1985</year><volume>82</volume><fpage>4245</fpage><lpage>4249</lpage><pub-id pub-id-type="doi">10.1073/pnas.82.12.4245</pub-id><pub-id pub-id-type="pmid">3159021</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masuda-Suzukake</surname><given-names>M</given-names></name><name><surname>Nonaka</surname><given-names>T</given-names></name></person-group><article-title>Pathological alpha-synuclein propagates through neural networks</article-title><source>Acta Neuropathol Comm</source><year>2014</year><volume>2</volume><fpage>88</fpage><pub-id pub-id-type="doi">10.1186/s40478-014-0088-8</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McAleese</surname><given-names>KE</given-names></name><name><surname>Walker</surname><given-names>L</given-names></name><name><surname>Erskine</surname><given-names>D</given-names></name><name><surname>Thomas</surname><given-names>AJ</given-names></name><name><surname>McKeith</surname><given-names>IG</given-names></name><name><surname>Attems</surname><given-names>J</given-names></name></person-group><article-title>TDP-43 pathology in Alzheimer&#x02019;s disease, dementia with Lewy bodies and ageing</article-title><source>Brain Pathol</source><year>2016</year><pub-id pub-id-type="pmid">27495267</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKeith</surname><given-names>IG</given-names></name><name><surname>Galasko</surname><given-names>D</given-names></name><name><surname>Kosaka</surname><given-names>K</given-names></name><name><surname>Perry</surname><given-names>EK</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name><name><surname>Hansen</surname><given-names>LA</given-names></name><name><surname>Salmon</surname><given-names>DP</given-names></name><name><surname>Lowe</surname><given-names>J</given-names></name><name><surname>Mirra</surname><given-names>SS</given-names></name><name><surname>Byrne</surname><given-names>EJ</given-names></name><etal/></person-group><article-title>Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop</article-title><source>Neurology</source><year>1996</year><volume>47</volume><fpage>1113</fpage><lpage>1124</lpage><pub-id pub-id-type="doi">10.1212/WNL.47.5.1113</pub-id><pub-id pub-id-type="pmid">8909416</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Micheva</surname><given-names>KD</given-names></name><name><surname>Smith</surname><given-names>SJ</given-names></name></person-group><article-title>Array tomography: a new tool for imaging the molecular architecture and ultrastructure of neural circuits</article-title><source>Neuron</source><year>2007</year><volume>55</volume><fpage>25</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2007.06.014</pub-id><pub-id pub-id-type="pmid">17610815</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mirra</surname><given-names>SS</given-names></name><name><surname>Heyman</surname><given-names>A</given-names></name><name><surname>McKeel</surname><given-names>D</given-names></name><name><surname>Sumi</surname><given-names>SM</given-names></name><name><surname>Crain</surname><given-names>BJ</given-names></name><name><surname>Brownlee</surname><given-names>LM</given-names></name><name><surname>Vogel</surname><given-names>FS</given-names></name><name><surname>Hughes</surname><given-names>JP</given-names></name><name><surname>van Belle</surname><given-names>G</given-names></name><name><surname>Berg</surname><given-names>L</given-names></name></person-group><article-title>The Consortium to Establish a Registry for Alzheimer&#x02019;s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer&#x02019;s disease</article-title><source>Neurology</source><year>1991</year><volume>41</volume><fpage>479</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.1212/WNL.41.4.479</pub-id><pub-id pub-id-type="pmid">2011243</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molliex</surname><given-names>A</given-names></name><name><surname>Temirov</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Coughlin</surname><given-names>M</given-names></name><name><surname>Kanagaraj</surname><given-names>AP</given-names></name></person-group><article-title>Phase separation by low complexity domains promotes stress granule assembly and drives pathological fibrillization</article-title><source>Cell</source><year>2015</year><volume>163</volume><fpage>123</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.09.015</pub-id><pub-id pub-id-type="pmid">26406374</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreno</surname><given-names>F</given-names></name><name><surname>Rabinovici</surname><given-names>GD</given-names></name><name><surname>Karydas</surname><given-names>A</given-names></name><name><surname>Miller</surname><given-names>Z</given-names></name><name><surname>Hsu</surname><given-names>SC</given-names></name><name><surname>Legati</surname><given-names>A</given-names></name><name><surname>Fong</surname><given-names>J</given-names></name><name><surname>Schonhaut</surname><given-names>D</given-names></name><name><surname>Esselmann</surname><given-names>H</given-names></name><name><surname>Watson</surname><given-names>C</given-names></name><etal/></person-group><article-title>A novel mutation P112H in the TARDBP gene associated with frontotemporal lobar degeneration without motor neuron disease and abundant neuritic amyloid plaques</article-title><source>Acta Neuropathol Commun</source><year>2015</year><volume>3</volume><fpage>19</fpage><pub-id pub-id-type="doi">10.1186/s40478-015-0190-6</pub-id><pub-id pub-id-type="pmid">25853458</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mori</surname><given-names>K</given-names></name><name><surname>Weng</surname><given-names>SM</given-names></name><name><surname>Arzberger</surname><given-names>T</given-names></name><name><surname>May</surname><given-names>S</given-names></name><name><surname>Rentzsch</surname><given-names>K</given-names></name><name><surname>Kremmer</surname><given-names>E</given-names></name><name><surname>Schmid</surname><given-names>B</given-names></name><name><surname>Kretzschmar</surname><given-names>HA</given-names></name><name><surname>Cruts</surname><given-names>M</given-names></name><name><surname>Van Broeckhoven</surname><given-names>C</given-names></name><etal/></person-group><article-title>The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS</article-title><source>Science</source><year>2013</year><volume>339</volume><fpage>1335</fpage><lpage>1338</lpage><pub-id pub-id-type="doi">10.1126/science.1232927</pub-id><pub-id pub-id-type="pmid">23393093</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morimoto</surname><given-names>S</given-names></name><name><surname>Hatsuta</surname><given-names>H</given-names></name><name><surname>Kokubo</surname><given-names>Y</given-names></name><name><surname>Nakano</surname><given-names>Y</given-names></name><name><surname>Hasegawa</surname><given-names>M</given-names></name><name><surname>Yoneda</surname><given-names>M</given-names></name><name><surname>Hirokawa</surname><given-names>Y</given-names></name><name><surname>Kuzuhara</surname><given-names>S</given-names></name><name><surname>Shiraishi</surname><given-names>T</given-names></name><name><surname>Murayama</surname><given-names>S</given-names></name></person-group><article-title>Unusual tau pathology of the cerebellum in patients with amyotrophic lateral sclerosis/parkinsonism&#x02013;dementia complex from the kii peninsula, Japan</article-title><source>Brain Pathol</source><year>2017</year><pub-id pub-id-type="pmid">28236345</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>M</given-names></name><name><surname>Koyama</surname><given-names>A</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><name><surname>Mucke</surname><given-names>L</given-names></name></person-group><article-title>Tau reduction does not prevent motor deficits in two mouse models of Parkinson&#x02019;s disease</article-title><source>PLoS One</source><year>2011</year><volume>6</volume><fpage>e29257</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0029257</pub-id><pub-id pub-id-type="pmid">22206005</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moussaud</surname><given-names>S</given-names></name><name><surname>Jones</surname><given-names>DR</given-names></name><name><surname>Moussaud-Lamodiere</surname><given-names>EL</given-names></name><name><surname>Delenclos</surname><given-names>M</given-names></name><name><surname>Ross</surname><given-names>OA</given-names></name><name><surname>McLean</surname><given-names>PJ</given-names></name></person-group><article-title>Alpha-synuclein and tau: teammates in neurodegeneration?</article-title><source>Mol Neurodegener</source><year>2014</year><volume>9</volume><fpage>43</fpage><pub-id pub-id-type="doi">10.1186/1750-1326-9-43</pub-id><pub-id pub-id-type="pmid">25352339</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>PT</given-names></name><name><surname>Jicha</surname><given-names>GA</given-names></name><name><surname>Kryscio</surname><given-names>RJ</given-names></name><name><surname>Abner</surname><given-names>EL</given-names></name><name><surname>Schmitt</surname><given-names>FA</given-names></name><name><surname>Cooper</surname><given-names>G</given-names></name><name><surname>Xu</surname><given-names>LO</given-names></name><name><surname>Smith</surname><given-names>CD</given-names></name><name><surname>Markesbery</surname><given-names>WR</given-names></name></person-group><article-title>Low sensitivity in clinical diagnoses of dementia with Lewy bodies</article-title><source>J Neurol</source><year>2010</year><volume>257</volume><fpage>359</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1007/s00415-009-5324-y</pub-id><pub-id pub-id-type="pmid">19795154</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neumann</surname><given-names>M</given-names></name><name><surname>Kwong</surname><given-names>LK</given-names></name><name><surname>Truax</surname><given-names>AC</given-names></name><name><surname>Vanmassenhove</surname><given-names>B</given-names></name><name><surname>Kretzschmar</surname><given-names>HA</given-names></name><name><surname>Van Deerlin</surname><given-names>VM</given-names></name><name><surname>Clark</surname><given-names>CM</given-names></name><name><surname>Grossman</surname><given-names>M</given-names></name><name><surname>Miller</surname><given-names>BL</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><etal/></person-group><article-title>TDP-43-positive white matter pathology in frontotemporal lobar degeneration with ubiquitin-positive inclusions</article-title><source>J Neuropathol Exp Neurol</source><year>2007</year><volume>66</volume><fpage>177</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1097/01.jnen.0000248554.45456.58</pub-id><pub-id pub-id-type="pmid">17356379</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neumann</surname><given-names>M</given-names></name><name><surname>Sampathu</surname><given-names>DM</given-names></name><name><surname>Kwong</surname><given-names>LK</given-names></name><name><surname>Truax</surname><given-names>AC</given-names></name><name><surname>Micsenyi</surname><given-names>MC</given-names></name><name><surname>Chou</surname><given-names>TT</given-names></name><name><surname>Bruce</surname><given-names>J</given-names></name><name><surname>Schuck</surname><given-names>T</given-names></name><name><surname>Grossman</surname><given-names>M</given-names></name><name><surname>Clark</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis</article-title><source>Science</source><year>2006</year><volume>314</volume><fpage>130</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1126/science.1134108</pub-id><pub-id pub-id-type="pmid">17023659</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oddo</surname><given-names>S</given-names></name><name><surname>Billings</surname><given-names>L</given-names></name><name><surname>Kesslak</surname><given-names>JP</given-names></name><name><surname>Cribbs</surname><given-names>DH</given-names></name><name><surname>LaFerla</surname><given-names>FM</given-names></name></person-group><article-title>Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome</article-title><source>Neuron</source><year>2004</year><volume>43</volume><fpage>321</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2004.07.003</pub-id><pub-id pub-id-type="pmid">15294141</pub-id></element-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ono</surname><given-names>K</given-names></name><name><surname>Takahashi</surname><given-names>R</given-names></name><name><surname>Ikeda</surname><given-names>T</given-names></name><name><surname>Yamada</surname><given-names>M</given-names></name></person-group><article-title>Cross seeding effects of amyloid protein and synuclein</article-title><source>J Neurochem</source><year>2012</year><volume>122</volume><fpage>883</fpage><lpage>890</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2012.07847.x</pub-id><pub-id pub-id-type="pmid">22734715</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pastor</surname><given-names>P</given-names></name><name><surname>Moreno</surname><given-names>F</given-names></name><name><surname>Clarimon</surname><given-names>J</given-names></name><name><surname>Ruiz</surname><given-names>A</given-names></name><name><surname>Combarros</surname><given-names>O</given-names></name><name><surname>Calero</surname><given-names>M</given-names></name><name><surname>Lopez de Munain</surname><given-names>A</given-names></name><name><surname>Bullido</surname><given-names>MJ</given-names></name><name><surname>de Pancorbo</surname><given-names>MM</given-names></name><name><surname>Carro</surname><given-names>E</given-names></name><etal/></person-group><article-title>MAPT H1 haplotype is associated with late-onset Alzheimer&#x02019;s disease risk in APOE epsilon 4 noncarriers: results from the Dementia Genetics Spanish Consortium</article-title><source>J Alzheimers Dis</source><year>2015</year><volume>49</volume><fpage>343</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.3233/JAD-150555</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peelaerts</surname><given-names>W</given-names></name><name><surname>Bousset</surname><given-names>L</given-names></name><name><surname>Van der Perren</surname><given-names>A</given-names></name><name><surname>Moskalyuk</surname><given-names>A</given-names></name><name><surname>Pulizzi</surname><given-names>R</given-names></name><name><surname>Giugliano</surname><given-names>M</given-names></name><name><surname>Van den Haute</surname><given-names>C</given-names></name><name><surname>Melki</surname><given-names>R</given-names></name><name><surname>Baekelandt</surname><given-names>V</given-names></name></person-group><article-title>alpha-Synuclein strains cause distinct synucleinopathies after local and systemic administration</article-title><source>Nature</source><year>2015</year><volume>522</volume><fpage>340</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1038/nature14547</pub-id><pub-id pub-id-type="pmid">26061766</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pesiridis</surname><given-names>GS</given-names></name><name><surname>Tripathy</surname><given-names>K</given-names></name><name><surname>Tanik</surname><given-names>S</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Lee</surname><given-names>VM</given-names></name></person-group><article-title>A &#x0201c;two-hit&#x0201d; hypothesis for inclusion formation by carboxyl-terminal fragments of TDP-43 protein linked to RNA depletion and impaired microtubule-dependent transport</article-title><source>J Biol Chem</source><year>2011</year><volume>286</volume><fpage>18845</fpage><lpage>18855</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.231118</pub-id><pub-id pub-id-type="pmid">21454607</pub-id></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polymeropoulos</surname><given-names>MH</given-names></name><name><surname>Lavedan</surname><given-names>C</given-names></name><name><surname>Leroy</surname><given-names>E</given-names></name><name><surname>Ide</surname><given-names>SE</given-names></name><name><surname>Dehejia</surname><given-names>A</given-names></name><name><surname>Dutra</surname><given-names>A</given-names></name><name><surname>Pike</surname><given-names>B</given-names></name><name><surname>Root</surname><given-names>H</given-names></name><name><surname>Rubenstein</surname><given-names>J</given-names></name><name><surname>Boyer</surname><given-names>R</given-names></name><etal/></person-group><article-title>Mutation in the alpha-synuclein gene identified in families with Parkinson&#x02019;s disease</article-title><source>Science</source><year>1997</year><volume>276</volume><fpage>2045</fpage><lpage>2047</lpage><pub-id pub-id-type="doi">10.1126/science.276.5321.2045</pub-id><pub-id pub-id-type="pmid">9197268</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pooler</surname><given-names>AM</given-names></name><name><surname>Polydoro</surname><given-names>M</given-names></name><name><surname>Maury</surname><given-names>EA</given-names></name><name><surname>Nicholls</surname><given-names>SB</given-names></name><name><surname>Reddy</surname><given-names>SM</given-names></name><name><surname>Wegmann</surname><given-names>S</given-names></name><name><surname>William</surname><given-names>C</given-names></name><name><surname>Saqran</surname><given-names>L</given-names></name><name><surname>Cagsal-Getkin</surname><given-names>O</given-names></name><name><surname>Pitstick</surname><given-names>R</given-names></name><etal/></person-group><article-title>Amyloid accelerates tau propagation and toxicity in a model of early Alzheimer&#x02019;s disease</article-title><source>Acta Neuropathol Commun</source><year>2015</year><volume>3</volume><fpage>14</fpage><pub-id pub-id-type="doi">10.1186/s40478-015-0199-x</pub-id><pub-id pub-id-type="pmid">25853174</pub-id></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Renton</surname><given-names>AE</given-names></name><name><surname>Chi&#x000f2;</surname><given-names>A</given-names></name><name><surname>Traynor</surname><given-names>BJ</given-names></name></person-group><article-title>State of play in amyotrophic lateral sclerosis genetics</article-title><source>Nat Neurosci</source><year>2014</year><volume>17</volume><fpage>17</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1038/nn.3584</pub-id><pub-id pub-id-type="pmid">24369373</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Renton</surname><given-names>AE</given-names></name><name><surname>Majounie</surname><given-names>E</given-names></name><name><surname>Waite</surname><given-names>A</given-names></name><name><surname>Simon-Sanchez</surname><given-names>J</given-names></name><name><surname>Rollinson</surname><given-names>S</given-names></name><name><surname>Gibbs</surname><given-names>JR</given-names></name><name><surname>Schymick</surname><given-names>JC</given-names></name><name><surname>Laaksovirta</surname><given-names>H</given-names></name><name><surname>van Swieten</surname><given-names>JC</given-names></name><name><surname>Myllykangas</surname><given-names>L</given-names></name><etal/></person-group><article-title>A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD</article-title><source>Neuron</source><year>2011</year><volume>72</volume><fpage>257</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2011.09.010</pub-id><pub-id pub-id-type="pmid">21944779</pub-id></element-citation></ref><ref id="CR117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rijal Upadhaya</surname><given-names>A</given-names></name><name><surname>Kosterin</surname><given-names>I</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Von Arnim</surname><given-names>C</given-names></name><name><surname>Yamaguchi</surname><given-names>H</given-names></name><name><surname>F&#x000e4;ndrich</surname><given-names>M</given-names></name><name><surname>Walter</surname><given-names>J</given-names></name><name><surname>Thal</surname><given-names>DR</given-names></name></person-group><article-title>Biochemical stages of amyloid &#x003b2;-peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically-preclinical Alzheimer&#x02019;s disease</article-title><source>Brain</source><year>2014</year><volume>137</volume><fpage>887</fpage><lpage>903</lpage><pub-id pub-id-type="doi">10.1093/brain/awt362</pub-id><pub-id pub-id-type="pmid">24519982</pub-id></element-citation></ref><ref id="CR118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rijal Upadhaya</surname><given-names>A</given-names></name><name><surname>Scheibe</surname><given-names>F</given-names></name><name><surname>Kosterin</surname><given-names>I</given-names></name><name><surname>Abramowski</surname><given-names>D</given-names></name><name><surname>Gerth</surname><given-names>J</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Liebau</surname><given-names>S</given-names></name><name><surname>Yamaguchi</surname><given-names>H</given-names></name><name><surname>Walter</surname><given-names>J</given-names></name><name><surname>Staufenbiel</surname><given-names>M</given-names></name><etal/></person-group><article-title>The type of Abeta-related neuronal degeneration differs between amyloid precursor protein (APP23) and amyloid beta-peptide (APP48) transgenic mice</article-title><source>Acta Neuropathol Commun</source><year>2013</year><volume>1</volume><fpage>77</fpage><pub-id pub-id-type="doi">10.1186/2051-5960-1-77</pub-id><pub-id pub-id-type="pmid">24252227</pub-id></element-citation></ref><ref id="CR119"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberson</surname><given-names>ED</given-names></name><name><surname>Scearce-Levie</surname><given-names>K</given-names></name><name><surname>Palop</surname><given-names>JJ</given-names></name><name><surname>Yan</surname><given-names>F</given-names></name><name><surname>Cheng</surname><given-names>IH</given-names></name><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Gerstein</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>GQ</given-names></name><name><surname>Mucke</surname><given-names>L</given-names></name></person-group><article-title>Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer&#x02019;s disease mouse model</article-title><source>Science</source><year>2007</year><volume>316</volume><fpage>750</fpage><lpage>754</lpage><pub-id pub-id-type="doi">10.1126/science.1141736</pub-id><pub-id pub-id-type="pmid">17478722</pub-id></element-citation></ref><ref id="CR120"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogaev</surname><given-names>EI</given-names></name><name><surname>Sherrington</surname><given-names>R</given-names></name><name><surname>Rogaeva</surname><given-names>EA</given-names></name><name><surname>Levesque</surname><given-names>G</given-names></name><name><surname>Ikeda</surname><given-names>M</given-names></name><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>Chi</surname><given-names>H</given-names></name><name><surname>Lin</surname><given-names>C</given-names></name><name><surname>Holman</surname><given-names>K</given-names></name><name><surname>Tsuda</surname><given-names>T</given-names></name><etal/></person-group><article-title>Familial Alzheimer&#x02019;s disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer&#x02019;s disease type 3 gene</article-title><source>Nature</source><year>1995</year><volume>376</volume><fpage>775</fpage><lpage>778</lpage><pub-id pub-id-type="doi">10.1038/376775a0</pub-id><pub-id pub-id-type="pmid">7651536</pub-id></element-citation></ref><ref id="CR121"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schr&#x000f6;der</surname><given-names>R</given-names></name><name><surname>Watts</surname><given-names>GD</given-names></name><name><surname>Mehta</surname><given-names>SG</given-names></name><name><surname>Evert</surname><given-names>BO</given-names></name><name><surname>Broich</surname><given-names>P</given-names></name><name><surname>Fliessbach</surname><given-names>K</given-names></name><name><surname>Pauls</surname><given-names>K</given-names></name><name><surname>Hans</surname><given-names>VH</given-names></name><name><surname>Kimonis</surname><given-names>V</given-names></name><name><surname>Thal</surname><given-names>DR</given-names></name></person-group><article-title>Mutant valosin-containing protein causes a novel type of frontotemporal dementia</article-title><source>Ann Neurol</source><year>2005</year><volume>57</volume><fpage>457</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1002/ana.20407</pub-id><pub-id pub-id-type="pmid">15732117</pub-id></element-citation></ref><ref id="CR122"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sengupta</surname><given-names>U</given-names></name><name><surname>Guerrero-Mu&#x000f1;oz</surname><given-names>MJ</given-names></name><name><surname>Castillo-Carranza</surname><given-names>DL</given-names></name><name><surname>Lasagna-Reeves</surname><given-names>CA</given-names></name><name><surname>Gerson</surname><given-names>JE</given-names></name><name><surname>Paulucci-Holthauzen</surname><given-names>AA</given-names></name><name><surname>Krishnamurthy</surname><given-names>S</given-names></name><name><surname>Farhed</surname><given-names>M</given-names></name><name><surname>Jackson</surname><given-names>GR</given-names></name><name><surname>Kayed</surname><given-names>R</given-names></name></person-group><article-title>Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies</article-title><source>Biol Psychiat</source><year>2015</year><volume>78</volume><fpage>672</fpage><lpage>683</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2014.12.019</pub-id><pub-id pub-id-type="pmid">25676491</pub-id></element-citation></ref><ref id="CR123"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sepulcre</surname><given-names>J</given-names></name><name><surname>Schultz</surname><given-names>AP</given-names></name><name><surname>Sabuncu</surname><given-names>M</given-names></name><name><surname>Gomez-Isla</surname><given-names>T</given-names></name><name><surname>Chhatwal</surname><given-names>J</given-names></name><name><surname>Becker</surname><given-names>A</given-names></name><name><surname>Sperling</surname><given-names>R</given-names></name><name><surname>Johnson</surname><given-names>KA</given-names></name></person-group><article-title>In vivo tau, amyloid, and gray matter profiles in the aging brain</article-title><source>J Neurosci</source><year>2016</year><volume>36</volume><fpage>7364</fpage><lpage>7374</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0639-16.2016</pub-id><pub-id pub-id-type="pmid">27413148</pub-id></element-citation></ref><ref id="CR124"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shipton</surname><given-names>OA</given-names></name><name><surname>Leitz</surname><given-names>JR</given-names></name><name><surname>Dworzak</surname><given-names>J</given-names></name><name><surname>Acton</surname><given-names>CE</given-names></name><name><surname>Tunbridge</surname><given-names>EM</given-names></name><name><surname>Denk</surname><given-names>F</given-names></name><name><surname>Dawson</surname><given-names>HN</given-names></name><name><surname>Vitek</surname><given-names>MP</given-names></name><name><surname>Wade-Martins</surname><given-names>R</given-names></name><name><surname>Paulsen</surname><given-names>O</given-names></name><etal/></person-group><article-title>Tau protein is required for amyloid {beta}-induced impairment of hippocampal long-term potentiation</article-title><source>J Neurosci</source><year>2011</year><volume>31</volume><fpage>1688</fpage><lpage>1692</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2610-10.2011</pub-id><pub-id pub-id-type="pmid">21289177</pub-id></element-citation></ref><ref id="CR125"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sieczkowski</surname><given-names>E</given-names></name><name><surname>Milenkovic</surname><given-names>I</given-names></name><name><surname>Venkataramani</surname><given-names>V</given-names></name><name><surname>Giera</surname><given-names>R</given-names></name><name><surname>Strobel</surname><given-names>T</given-names></name><name><surname>Hoftberger</surname><given-names>R</given-names></name><name><surname>Liberski</surname><given-names>PP</given-names></name><name><surname>Auff</surname><given-names>E</given-names></name><name><surname>Wirths</surname><given-names>O</given-names></name><name><surname>Bayer</surname><given-names>TA</given-names></name><etal/></person-group><article-title>I716F AbetaPP mutation associates with the deposition of oligomeric pyroglutamate amyloid-beta and alpha-Synucleinopathy with Lewy bodies</article-title><source>J Alzheimers Dis</source><year>2015</year><volume>44</volume><fpage>103</fpage><lpage>114</lpage><pub-id pub-id-type="pmid">25182745</pub-id></element-citation></ref><ref id="CR126"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singleton</surname><given-names>AB</given-names></name><name><surname>Farrer</surname><given-names>M</given-names></name><name><surname>Johnson</surname><given-names>J</given-names></name><name><surname>Singleton</surname><given-names>A</given-names></name><name><surname>Hague</surname><given-names>S</given-names></name><name><surname>Kachergus</surname><given-names>J</given-names></name><name><surname>Hulihan</surname><given-names>M</given-names></name><name><surname>Peuralinna</surname><given-names>T</given-names></name><name><surname>Dutra</surname><given-names>A</given-names></name><name><surname>Nussbaum</surname><given-names>R</given-names></name><etal/></person-group><article-title>alpha-Synuclein locus triplication causes Parkinson&#x02019;s disease</article-title><source>Science</source><year>2003</year><volume>302</volume><fpage>841</fpage><pub-id pub-id-type="doi">10.1126/science.1090278</pub-id><pub-id pub-id-type="pmid">14593171</pub-id></element-citation></ref><ref id="CR127"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spinelli</surname><given-names>KJ</given-names></name><name><surname>Taylor</surname><given-names>JK</given-names></name><name><surname>Osterberg</surname><given-names>VR</given-names></name></person-group><article-title>Presynaptic alpha-synuclein aggregation in a mouse model of Parkinson&#x02019;s disease</article-title><source>J Neurosci</source><year>2014</year><volume>34</volume><fpage>2037</fpage><lpage>2050</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2581-13.2014</pub-id><pub-id pub-id-type="pmid">24501346</pub-id></element-citation></ref><ref id="CR128"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spires-Jones</surname><given-names>TL</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name></person-group><article-title>The intersection of amyloid beta and tau at synapses in Alzheimer&#x02019;s disease</article-title><source>Neuron</source><year>2014</year><volume>82</volume><fpage>756</fpage><lpage>771</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2014.05.004</pub-id><pub-id pub-id-type="pmid">24853936</pub-id></element-citation></ref><ref id="CR129"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sreedharan</surname><given-names>J</given-names></name><name><surname>Blair</surname><given-names>IP</given-names></name><name><surname>Tripathi</surname><given-names>VB</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Vance</surname><given-names>C</given-names></name><name><surname>Rogelj</surname><given-names>B</given-names></name><name><surname>Ackerley</surname><given-names>S</given-names></name><name><surname>Durnall</surname><given-names>JC</given-names></name><name><surname>Williams</surname><given-names>KL</given-names></name><name><surname>Buratti</surname><given-names>E</given-names></name><etal/></person-group><article-title>TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis</article-title><source>Science</source><year>2008</year><volume>319</volume><fpage>1668</fpage><lpage>1672</lpage><pub-id pub-id-type="doi">10.1126/science.1154584</pub-id><pub-id pub-id-type="pmid">18309045</pub-id></element-citation></ref><ref id="CR130"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>St George-Hyslop</surname><given-names>P</given-names></name><name><surname>Haines</surname><given-names>J</given-names></name><name><surname>Rogaev</surname><given-names>E</given-names></name><name><surname>Mortilla</surname><given-names>M</given-names></name><name><surname>Vaula</surname><given-names>G</given-names></name><name><surname>Pericak-Vance</surname><given-names>M</given-names></name><name><surname>Foncin</surname><given-names>JF</given-names></name><name><surname>Montesi</surname><given-names>M</given-names></name><name><surname>Bruni</surname><given-names>A</given-names></name><name><surname>Sorbi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Genetic evidence for a novel familial Alzheimer&#x02019;s disease locus on chromosome 14</article-title><source>Nat Genet</source><year>1992</year><volume>2</volume><fpage>330</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1038/ng1292-330</pub-id><pub-id pub-id-type="pmid">1303289</pub-id></element-citation></ref><ref id="CR131"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>St. George-Hyslop</surname><given-names>PH</given-names></name><name><surname>Tanzi</surname><given-names>RE</given-names></name><name><surname>Polinsky</surname><given-names>RJ</given-names></name><name><surname>Haines</surname><given-names>JL</given-names></name><name><surname>Nee</surname><given-names>L</given-names></name><name><surname>Watkins</surname><given-names>PC</given-names></name><name><surname>Myers</surname><given-names>RH</given-names></name><name><surname>Feldman</surname><given-names>RG</given-names></name><name><surname>Pollen</surname><given-names>D</given-names></name><name><surname>Drachman</surname><given-names>D</given-names></name><etal/></person-group><article-title>The genetic defect causing familial Alzheimer&#x02019;s disease maps on chromosome 21</article-title><source>Science</source><year>1987</year><volume>235</volume><fpage>885</fpage><lpage>890</lpage><pub-id pub-id-type="doi">10.1126/science.2880399</pub-id><pub-id pub-id-type="pmid">2880399</pub-id></element-citation></ref><ref id="CR132"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stefansson</surname><given-names>H</given-names></name><name><surname>Helgason</surname><given-names>A</given-names></name><name><surname>Thorleifsson</surname><given-names>G</given-names></name><name><surname>Steinthorsdottir</surname><given-names>V</given-names></name><name><surname>Masson</surname><given-names>G</given-names></name><name><surname>Barnard</surname><given-names>J</given-names></name><name><surname>Baker</surname><given-names>A</given-names></name><name><surname>Jonasdottir</surname><given-names>A</given-names></name><name><surname>Ingason</surname><given-names>A</given-names></name><name><surname>Gudnadottir</surname><given-names>VG</given-names></name><etal/></person-group><article-title>A common inversion under selection in Europeans</article-title><source>Nat Genet</source><year>2005</year><volume>37</volume><fpage>129</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1038/ng1508</pub-id><pub-id pub-id-type="pmid">15654335</pub-id></element-citation></ref><ref id="CR133"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>St&#x000f6;hr</surname><given-names>J</given-names></name><name><surname>Condello</surname><given-names>C</given-names></name><name><surname>Watts</surname><given-names>JC</given-names></name><name><surname>Bloch</surname><given-names>L</given-names></name><name><surname>Oehler</surname><given-names>A</given-names></name><name><surname>Nick</surname><given-names>M</given-names></name><name><surname>DeArmond</surname><given-names>SJ</given-names></name><name><surname>Giles</surname><given-names>K</given-names></name><name><surname>DeGrado</surname><given-names>WF</given-names></name><name><surname>Prusiner</surname><given-names>SB</given-names></name></person-group><article-title>Distinct synthetic A&#x003b2; prion strains producing different amyloid deposits in bigenic mice</article-title><source>Proc Natl Acad Sci USA</source><year>2014</year><volume>111</volume><fpage>10329</fpage><lpage>10334</lpage><pub-id pub-id-type="doi">10.1073/pnas.1408968111</pub-id><pub-id pub-id-type="pmid">24982137</pub-id></element-citation></ref><ref id="CR134"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sturchler-Pierrat</surname><given-names>C</given-names></name><name><surname>Abramowski</surname><given-names>D</given-names></name><name><surname>Duke</surname><given-names>M</given-names></name><name><surname>Wiederhold</surname><given-names>KH</given-names></name><name><surname>Mistl</surname><given-names>C</given-names></name><name><surname>Rothacher</surname><given-names>S</given-names></name><name><surname>Ledermann</surname><given-names>B</given-names></name><name><surname>Burki</surname><given-names>K</given-names></name><name><surname>Frey</surname><given-names>P</given-names></name><name><surname>Paganetti</surname><given-names>PA</given-names></name><etal/></person-group><article-title>Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology</article-title><source>Proc Natl Acad Sci USA</source><year>1997</year><volume>94</volume><fpage>13287</fpage><lpage>13292</lpage><pub-id pub-id-type="doi">10.1073/pnas.94.24.13287</pub-id><pub-id pub-id-type="pmid">9371838</pub-id></element-citation></ref><ref id="CR135"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swirski</surname><given-names>M</given-names></name><name><surname>Miners</surname><given-names>JS</given-names></name><name><surname>de Silva</surname><given-names>R</given-names></name><name><surname>Lashley</surname><given-names>T</given-names></name><name><surname>Ling</surname><given-names>H</given-names></name><name><surname>Holton</surname><given-names>J</given-names></name><name><surname>Revesz</surname><given-names>T</given-names></name><name><surname>Love</surname><given-names>S</given-names></name></person-group><article-title>Evaluating the relationship between amyloid-beta and alpha-synuclein phosphorylated at Ser129 in dementia with Lewy bodies and Parkinson&#x02019;s disease</article-title><source>Alzheimers Res Ther</source><year>2014</year><volume>6</volume><fpage>77</fpage><pub-id pub-id-type="doi">10.1186/s13195-014-0077-y</pub-id><pub-id pub-id-type="pmid">25452767</pub-id></element-citation></ref><ref id="CR136"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>RH</given-names></name><name><surname>Capetillo-Zarate</surname><given-names>E</given-names></name><name><surname>Lin</surname><given-names>MT</given-names></name><name><surname>Milner</surname><given-names>TA</given-names></name><name><surname>Gouras</surname><given-names>GK</given-names></name></person-group><article-title>Co-occurrence of Alzheimer&#x02019;s disease &#x003b2;-amyloid and tau pathologies at synapses</article-title><source>Neurobiol Aging</source><year>2010</year><volume>31</volume><fpage>1145</fpage><lpage>1152</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2008.07.021</pub-id><pub-id pub-id-type="pmid">18771816</pub-id></element-citation></ref><ref id="CR137"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanzi</surname><given-names>RE</given-names></name><name><surname>Gusella</surname><given-names>JF</given-names></name><name><surname>Watkins</surname><given-names>PC</given-names></name><name><surname>Bruns</surname><given-names>GA</given-names></name><name><surname>St. George-Hyslop</surname><given-names>P</given-names></name><name><surname>Van Keuren</surname><given-names>ML</given-names></name><name><surname>Patterson</surname><given-names>D</given-names></name><name><surname>Pagan</surname><given-names>S</given-names></name><name><surname>Kurnit</surname><given-names>DM</given-names></name><name><surname>Neve</surname><given-names>RL</given-names></name></person-group><article-title>Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus</article-title><source>Science</source><year>1987</year><volume>235</volume><fpage>880</fpage><lpage>884</lpage><pub-id pub-id-type="doi">10.1126/science.2949367</pub-id><pub-id pub-id-type="pmid">2949367</pub-id></element-citation></ref><ref id="CR138"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terry</surname><given-names>RD</given-names></name><name><surname>Peck</surname><given-names>A</given-names></name><name><surname>DeTeresa</surname><given-names>R</given-names></name><name><surname>Schechter</surname><given-names>R</given-names></name><name><surname>Horoupian</surname><given-names>DS</given-names></name></person-group><article-title>Some morphometric aspects of the brain in senile dementia of the Alzheimer type</article-title><source>Ann Neurol</source><year>1981</year><volume>10</volume><fpage>184</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1002/ana.410100209</pub-id><pub-id pub-id-type="pmid">7283403</pub-id></element-citation></ref><ref id="CR139"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thal</surname><given-names>DR</given-names></name><name><surname>Del Tredici</surname><given-names>K</given-names></name><name><surname>Ludolph</surname><given-names>AC</given-names></name><name><surname>Hoozemans</surname><given-names>JJ</given-names></name><name><surname>Rozemuller</surname><given-names>AJ</given-names></name><name><surname>Braak</surname><given-names>H</given-names></name><name><surname>Knippschild</surname><given-names>U</given-names></name></person-group><article-title>Stages of granulovacuolar degeneration: their relation to Alzheimer&#x02019;s disease and chronic stress response</article-title><source>Acta Neuropathol</source><year>2011</year><volume>122</volume><fpage>577</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1007/s00401-011-0871-6</pub-id><pub-id pub-id-type="pmid">21935637</pub-id></element-citation></ref><ref id="CR140"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thal</surname><given-names>DR</given-names></name><name><surname>Fandrich</surname><given-names>M</given-names></name></person-group><article-title>Protein aggregation in Alzheimer&#x02019;s disease: abeta and tau and their potential roles in the pathogenesis of AD</article-title><source>Acta Neuropathol</source><year>2015</year><volume>129</volume><fpage>163</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1007/s00401-015-1387-2</pub-id><pub-id pub-id-type="pmid">25600324</pub-id></element-citation></ref><ref id="CR141"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thal</surname><given-names>DR</given-names></name><name><surname>Ghebremedhin</surname><given-names>E</given-names></name><name><surname>Orantes</surname><given-names>M</given-names></name><name><surname>Wiestler</surname><given-names>OD</given-names></name></person-group><article-title>Vascular pathology in Alzheimer&#x02019;s disease: correlation of cerebral amyloid angiopathy and arteriosclerosis/lipohyalinosis with cognitive decline</article-title><source>J Neuropathol Exp Neurol</source><year>2003</year><volume>62</volume><fpage>1287</fpage><lpage>1301</lpage><pub-id pub-id-type="doi">10.1093/jnen/62.12.1287</pub-id><pub-id pub-id-type="pmid">14692704</pub-id></element-citation></ref><ref id="CR142"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thal</surname><given-names>DR</given-names></name><name><surname>Griffin</surname><given-names>WS</given-names></name><name><surname>Braak</surname><given-names>H</given-names></name></person-group><article-title>Parenchymal and vascular Abeta-deposition and its effects on the degeneration of neurons and cognition in Alzheimer&#x02019;s disease</article-title><source>J Cell Mol Med</source><year>2008</year><volume>12</volume><fpage>1848</fpage><lpage>1862</lpage><pub-id pub-id-type="doi">10.1111/j.1582-4934.2008.00411.x</pub-id><pub-id pub-id-type="pmid">18624777</pub-id></element-citation></ref><ref id="CR143"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thal</surname><given-names>DR</given-names></name><name><surname>R&#x000fc;b</surname><given-names>U</given-names></name><name><surname>Orantes</surname><given-names>M</given-names></name><name><surname>Braak</surname><given-names>H</given-names></name></person-group><article-title>Phases of Abeta-deposition in the human brain and its relevance for the development of AD</article-title><source>Neurology</source><year>2002</year><volume>58</volume><fpage>1791</fpage><lpage>1800</lpage><pub-id pub-id-type="doi">10.1212/WNL.58.12.1791</pub-id><pub-id pub-id-type="pmid">12084879</pub-id></element-citation></ref><ref id="CR144"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thal</surname><given-names>DR</given-names></name><name><surname>R&#x000fc;b</surname><given-names>U</given-names></name><name><surname>Schultz</surname><given-names>C</given-names></name><name><surname>Sassin</surname><given-names>I</given-names></name><name><surname>Ghebremedhin</surname><given-names>E</given-names></name><name><surname>Del Tredici</surname><given-names>K</given-names></name><name><surname>Braak</surname><given-names>E</given-names></name><name><surname>Braak</surname><given-names>H</given-names></name></person-group><article-title>Sequence of Abeta-protein deposition in the human medial temporal lobe</article-title><source>J Neuropathol Exp Neurol</source><year>2000</year><volume>59</volume><fpage>733</fpage><lpage>748</lpage><pub-id pub-id-type="doi">10.1093/jnen/59.8.733</pub-id><pub-id pub-id-type="pmid">10952063</pub-id></element-citation></ref><ref id="CR145"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thal</surname><given-names>DR</given-names></name><name><surname>Schultz</surname><given-names>C</given-names></name><name><surname>Botez</surname><given-names>G</given-names></name><name><surname>Del Tredici</surname><given-names>K</given-names></name><name><surname>Mrak</surname><given-names>RE</given-names></name><name><surname>Griffin</surname><given-names>WS</given-names></name><name><surname>Wiestler</surname><given-names>OD</given-names></name><name><surname>Braak</surname><given-names>H</given-names></name><name><surname>Ghebremedhin</surname><given-names>E</given-names></name></person-group><article-title>The impact of argyrophilic grain disease on the development of dementia and its relationship to concurrent Alzheimer&#x02019;s disease-related pathology</article-title><source>Neuropathol Appl Neurobiol</source><year>2005</year><volume>31</volume><fpage>270</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2990.2005.00635.x</pub-id><pub-id pub-id-type="pmid">15885064</pub-id></element-citation></ref><ref id="CR146"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thal</surname><given-names>DR</given-names></name><name><surname>von Arnim</surname><given-names>C</given-names></name><name><surname>Griffin</surname><given-names>WS</given-names></name><name><surname>Yamaguchi</surname><given-names>H</given-names></name><name><surname>Mrak</surname><given-names>RE</given-names></name><name><surname>Attems</surname><given-names>J</given-names></name><name><surname>Rijal Upadhaya</surname><given-names>A</given-names></name></person-group><article-title>Pathology of clinical and preclinical Alzheimer&#x02019;s disease</article-title><source>Eur Arch Psychiatry Clin Neurosci</source><year>2013</year><volume>263</volume><issue>Suppl 2</issue><fpage>S137</fpage><lpage>S145</lpage><pub-id pub-id-type="doi">10.1007/s00406-013-0449-5</pub-id><pub-id pub-id-type="pmid">24077890</pub-id></element-citation></ref><ref id="CR147"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thal</surname><given-names>DR</given-names></name><name><surname>von Arnim</surname><given-names>CA</given-names></name><name><surname>Griffin</surname><given-names>WS</given-names></name><name><surname>Mrak</surname><given-names>RE</given-names></name><name><surname>Walker</surname><given-names>L</given-names></name><name><surname>Attems</surname><given-names>J</given-names></name><name><surname>Arzberger</surname><given-names>T</given-names></name></person-group><article-title>Frontotemporal lobar degeneration FTLD-tau: preclinical lesions, vascular, and Alzheimer-related co-pathologies</article-title><source>J Neural Transm</source><year>2015</year><volume>122</volume><fpage>1007</fpage><lpage>1018</lpage><pub-id pub-id-type="doi">10.1007/s00702-014-1360-6</pub-id><pub-id pub-id-type="pmid">25556950</pub-id></element-citation></ref><ref id="CR148"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thal</surname><given-names>DR</given-names></name><name><surname>Zuchner</surname><given-names>S</given-names></name><name><surname>Gierer</surname><given-names>S</given-names></name><name><surname>Schulte</surname><given-names>C</given-names></name><name><surname>Schols</surname><given-names>L</given-names></name><name><surname>Schule</surname><given-names>R</given-names></name><name><surname>Synofzik</surname><given-names>M</given-names></name></person-group><article-title>Abnormal paraplegin expression in swollen neurites, tau- and alpha-Synuclein pathology in a case of hereditary spastic paraplegia SPG7 with an Ala510Val mutation</article-title><source>Int J Mol Sci</source><year>2015</year><volume>16</volume><fpage>25050</fpage><lpage>25066</lpage><pub-id pub-id-type="doi">10.3390/ijms161025050</pub-id><pub-id pub-id-type="pmid">26506339</pub-id></element-citation></ref><ref id="CR149"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsigelny</surname><given-names>IF</given-names></name><name><surname>Crews</surname><given-names>L</given-names></name><name><surname>Desplats</surname><given-names>P</given-names></name><name><surname>Shaked</surname><given-names>GM</given-names></name></person-group><article-title>Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer&#x02019;s and Parkinson&#x02019;s diseases</article-title><source>PLoS One</source><year>2008</year><pub-id pub-id-type="pmid">18769546</pub-id></element-citation></ref><ref id="CR150"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uchikado</surname><given-names>H</given-names></name><name><surname>Lin</surname><given-names>WL</given-names></name><name><surname>DeLucia</surname><given-names>MW</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name></person-group><article-title>Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy</article-title><source>J Neuropathol Exp Neurol</source><year>2006</year><volume>65</volume><fpage>685</fpage><lpage>697</lpage><pub-id pub-id-type="doi">10.1097/01.jnen.0000225908.90052.07</pub-id><pub-id pub-id-type="pmid">16825955</pub-id></element-citation></ref><ref id="CR151"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Um</surname><given-names>JW</given-names></name><name><surname>Kaufman</surname><given-names>AC</given-names></name><name><surname>Kostylev</surname><given-names>M</given-names></name><name><surname>Heiss</surname><given-names>JK</given-names></name><name><surname>Stagi</surname><given-names>M</given-names></name><name><surname>Takahashi</surname><given-names>H</given-names></name><name><surname>Kerrisk</surname><given-names>ME</given-names></name><name><surname>Vortmeyer</surname><given-names>A</given-names></name><name><surname>Wisniewski</surname><given-names>T</given-names></name><name><surname>Koleske</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer abeta oligomer bound to cellular prion protein</article-title><source>Neuron</source><year>2013</year><volume>79</volume><fpage>887</fpage><lpage>902</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2013.06.036</pub-id><pub-id pub-id-type="pmid">24012003</pub-id></element-citation></ref><ref id="CR152"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Umeda</surname><given-names>T</given-names></name><name><surname>Maekawa</surname><given-names>S</given-names></name><name><surname>Kimura</surname><given-names>T</given-names></name><name><surname>Takashima</surname><given-names>A</given-names></name><name><surname>Tomiyama</surname><given-names>T</given-names></name><name><surname>Mori</surname><given-names>H</given-names></name></person-group><article-title>Neurofibrillary tangle formation by introducing wild-type human tau into APP transgenic mice</article-title><source>Acta Neuropathol</source><year>2014</year><volume>127</volume><fpage>685</fpage><lpage>698</lpage><pub-id pub-id-type="doi">10.1007/s00401-014-1259-1</pub-id><pub-id pub-id-type="pmid">24531886</pub-id></element-citation></ref><ref id="CR153"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uryu</surname><given-names>K</given-names></name><name><surname>Nakashima-Yasuda</surname><given-names>H</given-names></name><name><surname>Forman</surname><given-names>MS</given-names></name><name><surname>Kwong</surname><given-names>LK</given-names></name><name><surname>Clark</surname><given-names>CM</given-names></name><name><surname>Grossman</surname><given-names>M</given-names></name><name><surname>Miller</surname><given-names>BL</given-names></name><name><surname>Kretzschmar</surname><given-names>HA</given-names></name><name><surname>Lee</surname><given-names>VM</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><etal/></person-group><article-title>Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies</article-title><source>J Neuropathol Exp Neurol</source><year>2008</year><volume>67</volume><fpage>555</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.1097/NEN.0b013e31817713b5</pub-id><pub-id pub-id-type="pmid">18520774</pub-id></element-citation></ref><ref id="CR154"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volpicelli-Daley</surname><given-names>LA</given-names></name><name><surname>Luk</surname><given-names>KC</given-names></name><name><surname>Patel</surname><given-names>TP</given-names></name><name><surname>Tanik</surname><given-names>SA</given-names></name><name><surname>Riddle</surname><given-names>DM</given-names></name><name><surname>Stieber</surname><given-names>A</given-names></name><name><surname>Meaney</surname><given-names>DF</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Lee</surname><given-names>VM</given-names></name></person-group><article-title>Exogenous &#x003b1;-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death</article-title><source>Neuron</source><year>2011</year><volume>72</volume><fpage>57</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2011.08.033</pub-id><pub-id pub-id-type="pmid">21982369</pub-id></element-citation></ref><ref id="CR155"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wade-Martins</surname><given-names>R</given-names></name></person-group><article-title>Genetics: the MAPT locus&#x02014;a genetic paradigm in disease susceptibility</article-title><source>Nat Rev Neurol</source><year>2012</year><volume>8</volume><fpage>477</fpage><lpage>478</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2012.169</pub-id><pub-id pub-id-type="pmid">22940644</pub-id></element-citation></ref><ref id="CR156"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>L</given-names></name><name><surname>McAleese</surname><given-names>KE</given-names></name><name><surname>Thomas</surname><given-names>AJ</given-names></name><name><surname>Johnson</surname><given-names>M</given-names></name><name><surname>Martin-Ruiz</surname><given-names>C</given-names></name><name><surname>Parker</surname><given-names>C</given-names></name><name><surname>Colloby</surname><given-names>SJ</given-names></name><name><surname>Jellinger</surname><given-names>K</given-names></name><name><surname>Attems</surname><given-names>J</given-names></name></person-group><article-title>Neuropathologically mixed Alzheimer&#x02019;s and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes</article-title><source>Acta Neuropathol</source><year>2015</year><volume>129</volume><fpage>729</fpage><lpage>748</lpage><pub-id pub-id-type="doi">10.1007/s00401-015-1406-3</pub-id><pub-id pub-id-type="pmid">25758940</pub-id></element-citation></ref><ref id="CR157"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walls</surname><given-names>KC</given-names></name><name><surname>Ager</surname><given-names>RR</given-names></name><name><surname>Vasilevko</surname><given-names>V</given-names></name><name><surname>Cheng</surname><given-names>D</given-names></name><name><surname>Medeiros</surname><given-names>R</given-names></name><name><surname>LaFerla</surname><given-names>FM</given-names></name></person-group><article-title>p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice</article-title><source>Neurosci Lett</source><year>2014</year><volume>575</volume><fpage>96</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2014.05.047</pub-id><pub-id pub-id-type="pmid">24887583</pub-id></element-citation></ref><ref id="CR158"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watts</surname><given-names>GD</given-names></name><name><surname>Wymer</surname><given-names>J</given-names></name><name><surname>Kovach</surname><given-names>MJ</given-names></name><name><surname>Mehta</surname><given-names>SG</given-names></name><name><surname>Mumm</surname><given-names>S</given-names></name><name><surname>Darvish</surname><given-names>D</given-names></name><name><surname>Pestronk</surname><given-names>A</given-names></name><name><surname>Whyte</surname><given-names>MP</given-names></name><name><surname>Kimonis</surname><given-names>VE</given-names></name></person-group><article-title>Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein</article-title><source>Nat Genet</source><year>2004</year><volume>36</volume><fpage>377</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1038/ng1332</pub-id><pub-id pub-id-type="pmid">15034582</pub-id></element-citation></ref><ref id="CR159"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watts</surname><given-names>JC</given-names></name><name><surname>Condello</surname><given-names>C</given-names></name><name><surname>St&#x000f6;hr</surname><given-names>J</given-names></name><name><surname>Oehler</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>DeArmond</surname><given-names>SJ</given-names></name><name><surname>Lannfelt</surname><given-names>L</given-names></name><name><surname>Ingelsson</surname><given-names>M</given-names></name><name><surname>Giles</surname><given-names>K</given-names></name><name><surname>Prusiner</surname><given-names>SB</given-names></name></person-group><article-title>Serial propagation of distinct strains of A&#x003b2; prions from Alzheimer&#x02019;s disease patients</article-title><source>Proc Natl Acad Sci USA</source><year>2014</year><volume>111</volume><fpage>10323</fpage><lpage>10328</lpage><pub-id pub-id-type="doi">10.1073/pnas.1408900111</pub-id><pub-id pub-id-type="pmid">24982139</pub-id></element-citation></ref><ref id="CR160"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wills</surname><given-names>J</given-names></name><name><surname>Credle</surname><given-names>J</given-names></name><name><surname>Haggerty</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Oaks</surname><given-names>AW</given-names></name><name><surname>Sidhu</surname><given-names>A</given-names></name></person-group><article-title>Tauopathic changes in the striatum of A53T alpha-synuclein mutant mouse model of Parkinson&#x02019;s disease</article-title><source>PLoS One</source><year>2011</year><volume>6</volume><fpage>e17953</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0017953</pub-id><pub-id pub-id-type="pmid">21445308</pub-id></element-citation></ref><ref id="CR161"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolfe</surname><given-names>MS</given-names></name><name><surname>Xia</surname><given-names>W</given-names></name><name><surname>Ostaszewski</surname><given-names>BL</given-names></name><name><surname>Diehl</surname><given-names>TS</given-names></name><name><surname>Kimberly</surname><given-names>WT</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name></person-group><article-title>Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity</article-title><source>Nature</source><year>1999</year><volume>398</volume><fpage>513</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1038/19077</pub-id><pub-id pub-id-type="pmid">10206644</pub-id></element-citation></ref><ref id="CR162"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Strong</surname><given-names>MJ</given-names></name></person-group><article-title>Widespread neuronal and glial hyperphosphorylated tau deposition in ALS with cognitive impairment</article-title><source>Amyotroph Lateral Scler</source><year>2012</year><volume>13</volume><fpage>178</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.3109/17482968.2011.622405</pub-id><pub-id pub-id-type="pmid">22214313</pub-id></element-citation></ref><ref id="CR163"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zempel</surname><given-names>H</given-names></name><name><surname>Thies</surname><given-names>E</given-names></name><name><surname>Mandelkow</surname><given-names>E</given-names></name><name><surname>Mandelkow</surname><given-names>E-M</given-names></name></person-group><article-title>A&#x003b2; oligomers cause localized Ca2+ elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines</article-title><source>J Neurosci</source><year>2010</year><volume>30</volume><fpage>11938</fpage><lpage>11950</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2357-10.2010</pub-id><pub-id pub-id-type="pmid">20826658</pub-id></element-citation></ref></ref-list></back></article>